824 results on '"Charlier"'
Search Results
2. Reply to: Charlier et al. 2018. Mudslide and/or animal attack are more plausible causes and circumstances of death for AL 288 ('Lucy'): a forensic anthropology analysis
- Author
-
John, Kappelman, Richard A, Ketcham, Stephen, Pearce, Lawrence, Todd, Wiley, Akins, Matthew W, Colbert, Christopher, Davis, Mulugeta, Feseha, Jessica A, Maisano, and Adrienne, Witzel
- Subjects
Fractures, Bone ,Cause of Death ,Animals ,Forensic Anthropology ,Humans ,Accidental Falls ,Female ,Hominidae ,Ethiopia ,Landslides - Abstract
The Pliocene hominin fossil 'Lucy' (A.L. 288-1
- Published
- 2019
3. Sister chromatid exchange data and Gram-Charlier series
- Author
-
Marvin A. Kastenbaum, Wesley Eddings, L. R. Shenton, and Kimiko o Bowman
- Subjects
Male ,Biometry ,Models, Statistical ,Binomial (polynomial) ,Health, Toxicology and Mutagenesis ,Smoking ,Negative binomial distribution ,Asymptotic distribution ,Poisson distribution ,Combinatorics ,symbols.namesake ,Distribution (mathematics) ,Goodness of fit ,Data Interpretation, Statistical ,Genetics ,Chi-square test ,symbols ,Humans ,Probability distribution ,Female ,Sister Chromatid Exchange ,Molecular Biology ,Statistical Distributions ,Mathematics - Abstract
Bowman et al. [K.O. Bowman, M.A. Kastenbaum, L.R. Shenton, Fitting multi-parameter distributions to SCE data, Mutat. Res., 358 (1996) 15-24.] showed how discrete Pearson and discrete Johnson translation-system distributions may be fitted to sister chromatid exchange (SCE) data presented by Bender et al. [M.A. Bender, R.J. Pearston, R.C. Leonard, B.E. Pyatt, P.C. Gooch, On the distribution of spontaneous SCE in human peripheral blood lymphocytes, Mutat. Res., 281 (1992) 227-232.]. When their performances were measured by the chi-squared test of goodness of fit, these distributions proved to be only moderately better alternatives to the poorly fitting Poisson, binomial, and negative binomial distributions. In this paper, we extend our search for better characterizations of the SCE data by calling upon the Gram-Charlier type B approximation of the negative binomial distribution. We introduce an innovative extension of methods described in a little-known paper by Aitken and Gonin [A.C. Aitken, H.T. Gonin, On fourfold sampling with and without replacement, Proc. R. Soc. Edinburgh, 55 (1934) 114-125.], and show how this leads to fits of the SCE data that, in general, are within acceptable levels of probability. Moreover, we show how a theorem by Cramér [H. Cramér, Mathematical Methods of Statistics, Princeton Univ. Press, 1946.], relating to the scale factor m2/m'1 and its asymptotic distribution, may be used to discriminate between smokers and nonsmokers of the same gender.
- Published
- 1998
4. Controversial identification in a historical case is illustrative of the complexity of DNA typing in forensic research. Response to Charlier et al
- Author
-
Maarten Larmuseau, Jean-Jacques Cassiman, and Ronny Decorte
- Subjects
Genetics ,Male ,Famous Persons ,Genetic data ,Media coverage ,Biology ,DNA Fingerprinting ,DNA, Mitochondrial ,Genealogy ,Pathology and Forensic Medicine ,Forensic science ,DNA profiling ,Humans ,Identification (biology) ,Degraded dna ,Typing ,Famous persons - Abstract
The previously published genetic identification of presumptive samples attributed to two French kings, Henri IV and Louis XVI, by Charlier et al., was recently refuted by a genetic genealogic approach. This (provisional) refutation illustrates the difficulties in confirming the identification of historical DNA samples using limited genetic data. Therefore, we want to stress the necessity of including the genetic genealogic approach--which relies on DNA typing of living relatives of the presumptive donor as a confirmed reference--to validate genetic results in historical cases. Moreover, the popularity and broad media coverage of such studies are useful in bringing awareness to the general public, non-DNA forensic experts and lawyers about the complexity of DNA typing in forensic cases.
- Published
- 2013
5. Fasciola and fasciolosis in ruminants in Europe: Identifying research needs
- Author
-
Beesley, N. J., Caminade, C., Charlier, J., Flynn, R. J., Hodgkinson, J. E., Martinez‐Moreno, A., Martinez‐Valladares, M., Perez, J., Rinaldi, L., Williams, D. J. L., European Commission, Ministerio de Economía y Competitividad (España), Biotechnology and Biological Sciences Research Council (UK), Consejo Superior de Investigaciones Científicas (España), University of Liverpool, Beesley, N J, Caminade, C, Charlier, J, Flynn, R J, Hodgkinson, J E, Martinez-Moreno, A, Martinez-Valladares, M, Perez, J, Rinaldi, L, and Williams, CHRISTOPHER JOHN
- Subjects
Fascioliasis ,Discontools Supplement ,Cattle Diseases ,Sheep Diseases ,Socio-economics of parasite infection ,Flukicide resistance ,Galba ,Communicable Diseases, Emerging ,Research gaps ,Diagnosis ,Prevalence ,DISCONTOOLS Supplement: Current research gaps for advancing control of infectious diseases in production animals. Guest Editors: J. Charlier and H.W. Barkema ,Animals ,Humans ,Transmission ,Anthelmintics ,research gap ,Goat Diseases ,Sheep ,Goats ,Vaccination ,Ruminants ,Fasciola hepatica ,Europe ,diagnosi ,Cattle ,socio‐economics of parasite infection ,Fluke ,Helminth immunomodulation ,Fluke vaccine - Abstract
18 páginas, 1 figura, 2 tablas., Fasciola hepatica is a trematode parasite with a global distribution, which is responsible for considerable disease and production losses in a range of food producing species. It is also identified by WHO as a re-emerging neglected tropical disease associated with endemic and epidemic outbreaks of disease in human populations. In Europe, F. hepatica is mostly associated with disease in sheep, cattle and goats. This study reviews the most recent advances in our understanding of the transmission, diagnosis, epidemiology and the economic impact of fasciolosis. We also focus on the impact of the spread of resistance to anthelmintics used to control F. hepatica and consider how vaccines might be developed and applied in the context of the immune-modulation driven by the parasite. Several major research gaps are identified which, when addressed, will contribute to providing focussed and where possible, bespoke, advice for farmers on how to integrate stock management and diagnosis with vaccination and/or targeted treatment to more effectively control the parasite in the face of increasing the prevalence of infection and spread of anthelmintic resistance that are likely to be exacerbated by climate change., All authors are members of the Livestock Helminth Research Alliance (LiHRA), whose vision is to improve the health, wealth and productivity of European livestock by providing sustainable helminth control options. This review was commissioned by DISCONTOOLS (www.discontools.eu) as part of the process of identifying research gaps which impinge on effective and sustainable control of fasciolosis in food producing animals in Europe. DJLW, JC, LR, CC, JPA, AMM all received funding from the European Union through the following awards: FPVI‐FOOD‐CT‐200X‐023025‐DELIVER; FPVII‐KBBE‐2011‐5‐288975‐GLOWORM; FPVII‐KBBE‐2010‐4‐265862‐PARAVAC; H2020‐635408‐PARAGONE. DJLW, JEH, NJB received funding from the Biotechnology and Biological Sciences Research Council (BBSRC) through awards: BB/K015591/1 and BBI002480/1, and RJF was supported by BBSRC award BB/M018520/1. MMV was funded by the Spanish “Ramón y Cajal” Programme of the Ministry of Economy and Competitiveness (RYC‐2015‐18368). CC was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at the University of Liverpool in partnership with Public Health England (PHE) and Liverpool School of Tropical Medicine (LSTM). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or PHE.
- Published
- 2018
6. The Role of Titanium Dioxide (E171) and the Requirements for Replacement Materials in Oral Solid Dosage Forms: An IQ Consortium Working Group Review
- Author
-
Ross Blundell, Paul Butterworth, Anne Charlier, Dominick Daurio, Matthias Degenhardt, David Harris, Bruno Hancock, Megan Johnston, Ram Kasina, Jonathan Kaye, Ron Kelly, Philip Lienbacher, Liz Meehan, Jason Melnick, Peter Ojakovo, Jochen Schoell, Bernhard Schimmelle, Mike Tobyn, Leonie Wagner-Hattler, Joanne Wakeman, and Raphael Wiedey
- Subjects
Excipients ,Titanium ,Talc ,Humans ,Pharmaceutical Science ,Food Additives ,Starch ,Calcium Carbonate ,Tablets - Abstract
Titanium dioxide (in the form of E171) is a ubiquitous excipient in tablets and capsules for oral use. In the coating of a tablet or in the shell of a capsule the material disperses visible and UV light so that the contents are protected from the effects of light, and the patient or caregiver cannot see the contents within. It facilitates elegant methods of identification for oral solid dosage forms, thus aiding in the battle against counterfeit products. Titanium dioxide ensures homogeneity of appearance from batch to batch fostering patient confidence. The ability of commercial titanium dioxide to disperse light is a function of the natural properties of the anatase polymorph of titanium dioxide, and the manufacturing processes used to produce the material utilized in pharmaceuticals. In some jurisdictions E171 is being considered for removal from pharmaceutical products, as a consequence of it being delisted as an approved colorant for foods. At the time of writing, in the view of the authors, no system or material which could address both current and future toxicological concerns of Regulators and the functional needs of the pharmaceutical industry and patients has been identified. This takes into account the assessment of materials such as calcium carbonate, talc, isomalt, starch and calcium phosphates. In this paper an IQ Consortium team outlines the properties of titanium dioxide and criteria to which new replacement materials should be held.
- Published
- 2022
7. Hippocrates: father of mini-invasive nasal surgery
- Author
-
Nadia, Benmoussa, Grégoire, D'andrea, Antoine, Moya-Plana, and Charlier, Philippe
- Subjects
Nasal Polyps ,Nasal Surgical Procedures ,Humans ,Radiology, Nuclear Medicine and imaging ,Surgery ,Nose ,Anatomy ,Pathology and Forensic Medicine - Abstract
Hippocrates, a Greek physician during the fifth century BC., is often considered the father of medicine. The Corpus Hippocraticum comprising of 58 volumes was writing between 450 and 150 BC. The objective of our study was to detail the management of nasal polyps during this period. We read and analyzed all volumes of the Corpus Hippocraticum in French translation and extracted all passages dealing with nasal polyps (n = 6). Surgical procedures in the Corpus Hippocraticum are described in great detail. The first surgical strategy for the removal of nasal polyps was by mini-invasive nasal approach: the lopping method and the sponge method. We explain the two mini-invasive nasal approaches with drawings. The meticulously detailed observations of the corpus give us a precious insight into the early perception of diseases, their progression and early attempts of treatment.
- Published
- 2022
8. Assessing signs of torture: A review of clinical forensic dermatology
- Author
-
Patrícia Duarte Deps, Hugo Pessotti Aborghetti, Julienne Dadalto dos Santos, Philippe Charlier, Simon M Collin, Taís Loureiro Zambon, and Victória Coutinho Costa
- Subjects
Refugees ,medicine.medical_specialty ,Torture ,business.industry ,Refugee ,Perforation (oil well) ,Scars ,Dermatology ,Forensic Medicine ,Skin Diseases ,Cicatrix ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Sharp Instruments ,0302 clinical medicine ,Blunt ,030220 oncology & carcinogenesis ,medicine ,Humans ,Medical assessment ,medicine.symptom ,business ,Medical attention - Abstract
Background It is important for dermatologists and other physicians in refugee-receiving countries to acquire knowledge of forensic dermatology to identify lesions from torture. Objective Review forensic dermatology in cases of torture. Results In providing medical assessment and care to refugees and migrants, chronic skin lesions will be the most readily identifiable signs of torture. Beatings are very common, with blunt force trauma resulting in post-inflammatory hyperpigmentation. Torture burns can be thermal, chemical or electrothermal, causing distinct lesions determined by the method, duration and intensity of exposure, and area of skin affected. Sharp instruments inflict a wide range of lesions arising from stabbing/perforation or cuts from knives. Wound healing without medical attention and in unsanitary conditions will affect the scarring process. Lesions from suspension and ligatures may occur alongside scars from other forms of torture. Differential diagnoses include self-inflicted wounds, ethnic scarification and scars from traditional healing practices. Conclusion Physicians who may encounter survivors of torture in community or specialist practice would benefit from basic training in forensic dermatology, whilst knowledge of common forms of torture and cultural practices in refugees’ countries of origin is important when considering differential diagnoses of skin lesions.
- Published
- 2022
9. Toxicological analysis of a 'poison vial' found in the remains of an SS soldier (Maltot, Normandy, France)
- Author
-
Philippe Charlier, Dominique Corde, Virginie Bourdin, Thierry Martin, Vincent Tessier, Mel Donnelly, Adeline Knapp, and Jean-Claude Alvarez
- Subjects
Male ,Narcotics ,Cyanides ,Ethanol ,Methanol ,Amphetamines ,Water ,General Medicine ,Ether ,Poisons ,Arsenic ,Pathology and Forensic Medicine ,Military Personnel ,Tandem Mass Spectrometry ,Solvents ,Humans ,Chloroform ,Chromatography, Liquid - Abstract
In Maltot (Normandy, France), one grave containing the remains of a German soldier, who died in 1944, was excavated amongst other graves and isolated elements. A dozen whole vials were unearthed, resulting in questions about their content. Various screenings were carried out on the contents of one single vial: HPLC-DAD and HR-LC-MS screening after 1/10 dilution in mobile phase, GC-MS and HS-GC-MS after 1/10 dilution in methanol, multi-element research by HR-ICP-MS after total mineralization, and cyanide analysis. Analyzed vial contained approximately 300 µL of a colorless, water-immiscible liquid with a characteristic solvent odor. HPLC-DAD, GC-MS, HR-LC-MS/MS, ICP-MS, and cyanide screenings were negative excluding the presence of cyanide, arsenic, barbiturates, amphetamines, or narcotics. HS-GC-MS analysis highlighted the presence of ethanol, chloroform, and diethyl ether at significant concentrations. Chloroform and diethyl ether were anesthetic products mainly reserved for urgent situations. We hypothesized that the soldier may have been a combat medic working on battlefields. as he was wounded, another possibility could be that he may have used the vials to relieve his pain; however, the immediate severity of the wounds drove us to assess the second hypothesis of delayed death as being less plausible. The high number of vials containing ethanol, chloroform, and diethyl ether, and the massive blood loss leading to quick death led us to support the combat medic or paramedic hypothesis.
- Published
- 2022
10. ProCaLung – Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium☆
- Author
-
Florian Charlier, Thomas Descamps, Yolande Lievens, Xavier Geets, Vincent Remouchamps, Maarten Lambrecht, Luigi Moretti, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'oncologie médicale
- Subjects
Observer Variation ,Practice guideline ,Lung Neoplasms ,Radiotherapy ,Radiotherapy Planning, Computer-Assisted ,Health care ,Mediastinum ,Hematology ,Quality assurance ,Benchmarking ,Belgium ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Qualitative research ,Humans ,Lymphatic irradiation ,Radiology, Nuclear Medicine and imaging ,Lymph Nodes - Abstract
The Quality Assurance project for stage III non-small cell lung cancer radiotherapy ProCaLung performed a multicentric two-step exercise evaluating mediastinal nodal Target Volume Definition and Delineation (TVD) variability and the opportunity for standardization. The TVD variability before and after providing detailed guidelines and the value of qualitative contour reviewing before applying quantitative measures were investigated. The case of a patient with stage III NSCLC and involved mediastinal lymph nodes was used as a basis for this study. Twenty-two radiation oncologists from nineteen centers in Belgium and Luxembourg participated in at least one of two phases of the project (before and after introduction of ProCaLung contouring guidelines). The resulting thirty-three mediastinal nodal GTV and CTV contours were then evaluated using a qualitative-before-quantitative (QBQ) approach. First, a qualitative analysis was performed, evaluating adherence to most recent guidelines. From this, a list of observed deviations was created and these were used to evaluate contour conformity. The second analysis was quantitative, using overlap and surface distance measures to compare contours within qualitative groups and between phases. A 'most robust' reference volume for these analyses was created using the STAPLE-algorithm and an averaging method. Five GTV and seven CTV qualitative groups were identified. Second step contours were more often in higher-conformity groups (p = 0.012 for GTV and p = 0.024 for CTV). Median Residual Mean Square Distances improved from 2.34 mm to 1.36 mm for GTV (p = 0.01) and from 4.53 mm to 1.58 mm for CTV (p
- Published
- 2022
11. Antioxidant Supplementation Hinders the Role of Exercise Training as a Natural Activator of SIRT1
- Author
-
Carmine Sellitto, Graziamaria Corbi, Berenice Stefanelli, Valentina Manzo, Marta Trucillo, Bruno Charlier, Francesca Mensitieri, Viviana Izzo, Angela Lucariello, Angelica Perna, Germano Guerra, Antonio De Luca, Amelia Filippelli, Valeria Conti, Sellitto, C, Corbi, G, Stefanelli, B, Manzo, V, Trucillo, M, Charlier, B, Mensitieri, F, Izzo, V, Lucariello, A, Perna, A, Guerra, G, De Luca, A, Filippelli, A, Conti, V., Sellitto, Carmine, Corbi, Graziamaria, Stefanelli, Berenice, Manzo, Valentina, Trucillo, Marta, Charlier, Bruno, Mensitieri, Francesca, Izzo, Viviana, Lucariello, Angela, Perna, Angelica, Guerra, Germano, De Luca, Antonio, Filippelli, Amelia, and Conti, Valeria
- Subjects
Nutrition and Dietetics ,Messenger ,antioxidant capacity ,athletes ,endurance training ,sirtuins ,vitamins ,Antioxidants ,sirtuin ,Sirtuin 1 ,Dietary Supplements ,Humans ,RNA ,RNA, Messenger ,athlete ,Exercise ,Food Science - Abstract
Exercise training (ET) is a natural activator of silent mating type information regulation 2 homolog 1 (SIRT1), a stress-sensor able to increase the endogenous antioxidant system. SIRT1 activators include polyphenols and vitamins, the antioxidant properties of which are well-known. Antioxidant supplements are used to improve athletic performance. However, they might blunt ET-related benefits. Middle-distance runners (MDR) taking (MDR-S) or not taking antioxidant supplements (MDR-NoS) were compared with each other and with sedentary subjects (CTR) to evaluate the ET effects on SIRT1 levels and oxidative stress, and to investigate whether an exogenous source of antioxidants could interfere with such effects. Thirty-two MDR and 14 CTR were enrolled. MDR-S took 240 mg vitamin C and 15 mg vitamin E together with mineral salts. SIRT1 mRNA and activity were measured in PBMCs. Total oxidative status (TOS) and total antioxidant capacity (TEAC) were determined in plasma. MDR showed higher levels of SIRT1 mRNA (p = 0.0387) and activity (p = 0.0055) than did CTR. MDR-NoS also showed higher levels than did MDR-S without reaching statistical significance. SIRT1 activity was higher (p = 0.0012) in MDR-NoS (1909 ± 626) than in MDR-S (1276 ± 474). TOS did not differ among the groups, while MDR showed higher TEAC levels than did CTR (2866 ± 581 vs. 2082 ± 560, p = 0.0001) as did MDR-S (2784 ± 643) and MDR-NoS (2919 ± 551) (MDR-S vs. CTR, p = 0.0007 and MDR-NoS vs. CTR, p = 0.003). TEAC (β = 0.4488356, 95% CI 0.2074645 0.6902067; p < 0.0001) and the MDR-NoS group (β = 744.6433, 95% CI 169.9954 1319.291; p= 0.012) predicted SIRT1 activity levels. Antioxidant supplementation seems to hinder the role of ET as a natural activator of SIRT1.
- Published
- 2022
12. It Takes a Village: A Novel Process for Responding to Emerging Issues in Agricultural Health and Safety
- Author
-
Megan Schossow, Devon Charlier, Suness Hall, and Jeff Bender
- Subjects
Public Health, Environmental and Occupational Health ,Humans ,Agriculture ,United States ,Occupational Health ,Crop Production - Abstract
Agricultural and food production systems are constantly evolving in response to societal and environmental factors. These sectors are also laden with occupational hazards, creating an opportunity for emerging and re-emerging issues such as emerging markets and changing worker demographics. The Upper Midwest is a region of intensive agricultural production, with many states leading the United States in livestock and crop production. As a National Institute of Occupational Safety and Health Center for Agricultural Safety and Health, the Upper Midwest Agricultural Safety and Health Center (UMASH) is tasked with protecting the health and safety of the region's agricultural workers. UMASH implements an Emerging Issues program to effectively respond to emerging and re-emerging issues impacting agricultural health and safety in the Upper Midwest. To direct such work, UMASH developed a novel Selection, Planning and Action Process Model. This model guides all stages of the UMASH Emerging Issues response and emphasizes the ongoing need for monitoring, evaluation, and feedback from agricultural communities. In conjunction with the UMASH Process Model, the International Association for Public Participation (IAP2) Spectrum of Public Participation frames the work of the Emerging Issues Program in meaningfully engaging the community of stakeholders across all stages.
- Published
- 2022
13. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapy
- Author
-
Lajaunie, Rébecca, Cuzin, Lise, Palich, Romain, Makinson, Alain, Bani-Sadr, Firouzé, Duvivier, Claudine, Arvieux, Cedric, Rey, David, Poizot-Martin, Isabelle, Delpierre, Cyril, Delobel, Pierre, Martin-Blondel, Guillaume, Chirouze, C., Drobacheff-Thiébaut, C., Foltzer, A., Bouiller, K., Hustache- Mathieu, L., Lepiller, Q., Bozon, F., Babre, O, Brunel, As., Muret, P., Chevalier, E., Jacomet, C., Laurichesse, H., Lesens, O., Vidal, M., Mrozek, N., Aumeran, C., Baud, O., Corbin, V., Goncalvez, E., Mirand, A, Brebion, A, Henquell, C, Lamaury, I., Fabre, I., Curlier, E., Ouissa, R., Herrmann-Storck, C., Tressieres, B., Receveur, Mc., Boulard, F., Daniel, C., Clavel, C., Roger, Pm., Markowicz, S., Chellum Rungen, N., Merrien, D., Perré, P., Guimard, T., Bollangier, O., Leautez, S., Morrier, M., Laine, L., Boucher, D., Point, P., Cotte, L., Ader, F., Becker, A., Boibieux, A., Brochier, C., Brunel-Dalmas, F., Cannesson, O., Chiarello, P., Chidiac, C., Degroodt, S., Ferry, T., Godinot, M., Livrozet, J.M., Makhloufi, D., Miailhes, P., Perpoint, T., Perry, M., Pouderoux, C., Roux, S., Triffault-Fillit, C., Valour, F., Charre, C., Icard, V., Tardy, J.C., Trabaud, M.A., Ravaux, I., Ménard, A., Belkhir, Ay., Colson, P., Dhiver, C., Madrid, A., Martin-Degioanni, M., Meddeb, L., Mokhtari, M., Motte, A., Raoux, A., Toméi, C., Tissot-Dupont, H., Poizot-Martin, I., Brégigeon, S., Zaegel-Faucher, O., Obry-Roguet, V., Laroche, H, Orticoni, M., Soavi, M.J., Ressiot, E., Ducassou, M.J., Jaquet, I., Galie, S., Colson, H., Ritleng, A.S., Ivanova, A., Debreux, C., Lions, C., Rojas-Rojas, T, Cabié, A., Abel, S., Bavay, J., Bigeard, B., Cabras, O., Cuzin, L., Dupin de Majoubert, R., Fagour, L., Guitteaud, K., Marquise, A., Najioullah, F., Pierre-François, S., Pasquier, J., Richard, P., Rome, K., Turmel, Jm, Varache, C., Atoui, N., Bistoquet, M., Delaporte, E, Le Moing, V., Makinson, A., Meftah, N., Merle de Boever, C., Montes, B., Montoya Ferrer, A., Tuaillon, E., Reynes, J., Lefèvre, B., Jeanmaire, E., Hénard, S., Frentiu, E., Charmillon, A., Legoff, A., Tissot, N., André, M., Boyer, L., Bouillon, Mp., Delestan, M., Goehringer, F., Bevilacqua, S., Rabaud, C., May, T., Raffi, F., Allavena, C., Aubry, O., Billaud, E., Biron, C., Bonnet, B., Bouchez, S., Boutoille, D., Brunet-Cartier, C., Deschanvres, C., Gaborit, B.J., Grégoire, A., Grégoire, M., Grossi, O., Guéry, R., Jovelin, T., Lefebvre, M., Le Turnier, P., Lecomte, R., Morineau, P., Reliquet, V., Sécher, S., Cavellec, M., Paredes, E., Soria, A., Ferré, V., André-Garnier, E., Rodallec, A., Pugliese, P., Breaud, S., Ceppi, C., Chirio, D., Cua, E., Dellamonica, P., Demonchy, E., de Monte, A., Durant, J., Etienne, C., Ferrando, S., Garraffo, R., Michelangeli, C., Mondain, V., Naqvi, A., Oran, N., Perbost, I., Carles, M., Klotz, C., Maka, A., Pradier, C., Prouvost-Keller, B., Risso, K., Rio, V., Rosenthal, E., Touitou, I., Wehrlen-Pugliese, S., Zouzou, G., Hocqueloux, L., Prazuck, T., Gubavu, C., Sève, A., Giaché, S., Rzepecki, V., Colin, M., Boulard, C., Thomas, G., Cheret, A., Goujard, C., Quertainmont, Y., Teicher, E., Lerolle, N., Jaureguiberry, S., Colarino, R., Deradji, O., Castro, A., Barrail-Tran, A., Yazdanpanah, Y., Landman, R., Joly, V., Ghosn, J., Rioux, C., Lariven, S., Gervais, A., Lescure, Fx., Matheron, S., Louni, F., Julia, Z., Le Gac, S., Charpentier, C., Descamps, D., Peytavin, G., Duvivier, C., Aguilar, C., Alby-Laurent, F., Amazzough, K., Benabdelmoumen, G., Bossi, P., Cessot, G., Charlier, C., Consigny, P.H., Jidar, K., Lafont, E., Lanternier, F., Leporrier, J., Lortholary, O., Louisin, C., Lourenco, J., Parize, P., Pilmis, B., Rouzaud, C., Touam, F., Valantin, Ma., Tubiana, R., Agher, R., Seang, Sophie, Schneider, L., Palich, R., Blanc, C., Katlama, C., Bani-Sadr, F., Berger, Jl., N’guyen, Y., Lambert, D., Kmiec, I., Hentzien, M., Brunet, A., Romaru, J., Marty, H., Brodard, V., Arvieux, C., Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat-Delon, S., Chapplain, J.M., Benezit, F., Dupont, M., Poinot, M., Maillard, A., Pronier, C., Lemaitre, F., Morlat, C., Poisson-Vannier, M., Sinteff, Jp., Gagneux-Brunon, A., Botelho-Nevers, E., Frésard, A., Ronat, V., Lucht, F., Rey, D., Fischer, P., Partisani, M., Cheneau, C., Priester, M., Batard, Ml., Mélounou, C, Bernard-Henry, C., de Mautort, E., Fafi-Kremer, S., Delobel, P., Alvarez, M., Biezunski, N., Debard, A., Delpierre, C., Gaube, G., Lansalot, P., Lelièvre, L., Marcel, M., Martin-Blondel, G., Piffaut, M., Porte, L., Saune, K., Robineau, O., Ajana, F., Aïssi, E., Alcaraz, I., Alidjinou, E., Baclet, V., Bocket, L., Boucher, A., Digumber, M., Huleux, T., Lafon-Desmurs, B., Meybeck, A., Pradier, M., Tetart, M., Thill, P., Viget, N., Valette, M., Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU de la Martinique [Fort de France], Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Reims (CHU Reims), Service des Maladies infectieuses et tropicales [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), CHU Pontchaillou [Rennes], CHU Strasbourg, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier - Faculté de médecine Purpan (UTPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), And The Dat’AIDS study group: C Chirouze, C Drobacheff-Thiébaut, A Foltzer, K Bouiller, L Hustache-Mathieu, Q Lepiller, F Bozon, O Babre, A S Brunel, P Muret, E Chevalier, C Jacomet, H Laurichesse, O Lesens, M Vidal, N Mrozek, C Aumeran, O Baud, V Corbin, E Goncalvez, A Mirand, A Brebion, C Henquell, I Lamaury, I Fabre, E Curlier, R Ouissa, C Herrmann-Storck, B Tressieres, M C Receveur, F Boulard, C Daniel, C Clavel, P M Roger, S Markowicz, N Chellum Rungen, D Merrien, P Perré, T Guimard, O Bollangier, S Leautez, M Morrier, L Laine, D Boucher, P Point, L Cotte, F Ader, A Becker, A Boibieux, C Brochier, F Brunel-Dalmas, O Cannesson, P Chiarello, C Chidiac, S Degroodt, T Ferry, M Godinot, J M Livrozet, D Makhloufi, P Miailhes, T Perpoint, M Perry, C Pouderoux, S Roux, C Triffault-Fillit, F Valour, C Charre, V Icard, J C Tardy, M A Trabaud, I Ravaux, A Ménard, A Y Belkhir, P Colson, C Dhiver, A Madrid, M Martin-Degioanni, L Meddeb, M Mokhtari, A Motte, A Raoux, C Toméi, H Tissot-Dupont, I Poizot-Martin, S Brégigeon, O Zaegel-Faucher, V Obry-Roguet, H Laroche, M Orticoni, M J Soavi, E Ressiot, M J Ducassou, I Jaquet, S Galie, H Colson, A S Ritleng, A Ivanova, C Debreux, C Lions, T Rojas-Rojas, A Cabié, S Abel, J Bavay, B Bigeard, O Cabras, L Cuzin, R Dupin de Majoubert, L Fagour, K Guitteaud, A Marquise, F Najioullah, S Pierre-François, J Pasquier, P Richard, K Rome, J M Turmel, C Varache, N Atoui, M Bistoquet, E Delaporte, V Le Moing, A Makinson, N Meftah, C Merle de Boever, B Montes, A Montoya Ferrer, E Tuaillon, J Reynes, B Lefèvre, E Jeanmaire, S Hénard, E Frentiu, A Charmillon, A Legoff, N Tissot, M André, L Boyer, M P Bouillon, M Delestan, F Goehringer, S Bevilacqua, C Rabaud, T May, F Raffi, C Allavena, O Aubry, E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet-Cartier, C Deschanvres, B J Gaborit, A Grégoire, M Grégoire, O Grossi, R Guéry, T Jovelin, M Lefebvre, P Le Turnier, R Lecomte, P Morineau, V Reliquet, S Sécher, M Cavellec, E Paredes, A Soria, V Ferré, E André-Garnier, A Rodallec, P Pugliese, S Breaud, C Ceppi, D Chirio, E Cua, P Dellamonica, E Demonchy, A De Monte, J Durant, C Etienne, S Ferrando, R Garraffo, C Michelangeli, V Mondain, A Naqvi, N Oran, I Perbost, M Carles, C Klotz, A Maka, C Pradier, B Prouvost-Keller, K Risso, V Rio, E Rosenthal, I Touitou, S Wehrlen-Pugliese, G Zouzou, L Hocqueloux, T Prazuck, C Gubavu, A Sève, S Giaché, V Rzepecki, M Colin, C Boulard, G Thomas, A Cheret, C Goujard, Y Quertainmont, E Teicher, N Lerolle, S Jaureguiberry, R Colarino, O Deradji, A Castro, A Barrail-Tran, Y Yazdanpanah, R Landman, V Joly, J Ghosn, C Rioux, S Lariven, A Gervais, F X Lescure, S Matheron, F Louni, Z Julia, S Le Gac, C Charpentier, D Descamps, G Peytavin, C Duvivier, C Aguilar, F Alby-Laurent, K Amazzough, G Benabdelmoumen, P Bossi, G Cessot, C Charlier, P H Consigny, K Jidar, E Lafont, F Lanternier, J Leporrier, O Lortholary, C Louisin, J Lourenco, P Parize, B Pilmis, C Rouzaud, F Touam, M A Valantin, R Tubiana, R Agher, S Seang, L Schneider, R Palich, C Blanc, C Katlama, F Bani-Sadr, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, A Brunet, J Romaru, H Marty, V Brodard, C Arvieux, P Tattevin, M Revest, F Souala, M Baldeyrou, S Patrat-Delon, J M Chapplain, F Benezit, M Dupont, M Poinot, A Maillard, C Pronier, F Lemaitre, C Morlat, M Poisson-Vannier, T Jovelin, J P Sinteff, A Gagneux-Brunon, E Botelho-Nevers, A Frésard, V Ronat, F Lucht, D Rey, P Fischer, M Partisani, C Cheneau, M Priester, M L Batard, C Mélounou, C Bernard-Henry, E de Mautort, S Fafi-Kremer, P Delobel, M Alvarez, N Biezunski, A Debard, C Delpierre, G Gaube, P Lansalot, L Lelièvre, M Marcel, G Martin-Blondel, M Piffaut, L Porte, K Saune, O Robineau, F Ajana, E Aïssi, I Alcaraz, E Alidjinou, V Baclet, L Bocket, A Boucher, M Digumber, T Huleux, B Lafon-Desmurs, A Meybeck, M Pradier, M Tetart, P Thill, N Viget, M Valette, Malbec, Odile, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT)-Université de Toulouse (UT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Rennes (CHU Rennes), Laboratoire de Physique des Lasers (LPL), Université Paris 13 (UP13)-Centre National de la Recherche Scientifique (CNRS)-Université Sorbonne Paris Nord, Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Institut des sciences de la santé publique [Marseille] (ISSPAM), European Infective Endocarditis Registry (Euro-Endo), EMERGEN consortium, Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Laboratoire Microorganismes : Génome et Environnement (LMGE), and Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)
- Subjects
medicine.medical_specialty ,MESH: CD4 Lymphocyte Count ,[SDV]Life Sciences [q-bio] ,antiretroviral therapy ,Human immunodeficiency virus (HIV) ,protease inhibitors ,HIV Infections ,medicine.disease_cause ,MESH: HIV-1 ,Acquired immunodeficiency syndrome (AIDS) ,MESH: Neoplasm Recurrence, Local / complications ,Internal medicine ,medicine ,Humans ,HHV8 ,MESH: HIV Infections* / complications ,MESH: Protease Inhibitors / adverse effects ,Pharmacology (medical) ,Protease inhibitor (pharmacology) ,Sarcoma, Kaposi ,Retrospective Studies ,MESH: Humans ,business.industry ,Health Policy ,Kaposi sarcoma ,MESH: Retrospective Studies ,Viral Load ,MESH: HIV Infections* / drug therapy ,medicine.disease ,Antiretroviral therapy ,switch ,CD4 Lymphocyte Count ,AIDS ,[SDV] Life Sciences [q-bio] ,Regimen ,Infectious Diseases ,Increased risk ,MESH: Sarcoma, Kaposi* / drug therapy ,HIV-1 ,Sarcoma ,Neoplasm Recurrence, Local ,business ,MESH: Viral Load ,Viral load - Abstract
International audience; Objectives: Our aim was to assess if switching from a protease inhibitors (PI)-based regimen to a PI-free one is associated with an increased risk of Kaposi Sarcoma (KS) relapse among patients living with HIV (PLHIV) with history of KS and controlled HIV replication.Methods: In a retrospective analysis of the prospectively collected Dat'AIDS database we selected patients who both had a past KS history and a HIV-1 viral load below 200 copies/mL while being PI-treated. We searched for KS relapses while persistent virological success was maintained for at least 6 months, whether patients kept taking the PI, or switched to PI-free regimen.Results: Among the 216 patients with past KS event and a history of HIV-1 infection efficiently treated by a PI-based regimen, 148 patients (68.5%) later switched to a PI-sparing regimen. Their baseline characteristics were not different from non-switching patients. We described 7 cases of relapse (3.2% of the 216 patients). Five cases of relapse occurred in switching patients (3.4%). The remaining two relapses occurred in PI-treated patients (2.9%). At KS relapse, CD4 cell count was 459 cells/μL (range 225-560) for switching patients, compared with 362 and 136 cells/μL for the other two patients.Conclusions: In this large cohort of PLHIV with a history of KS and ART-controlled HIV replication, KS relapses were described in 3.2% of the patients, and were not more frequent when a PI-containing ART regimen has been switched to a PI-free regimen. Our results do not support a specific effect of PI on KS.
- Published
- 2022
14. Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates
- Author
-
Omar Elkayal, Erwin Dreesen, Karel Allegaert, Anne Smits, Corinne Charlier, Isabel Spriet, Marie-Christine Seghaye, and Pharmacy
- Subjects
Adult ,Microbiology (medical) ,Population ,Cefazolin ,Umbilical cord ,Streptococcus agalactiae ,Umbilical Cord ,Plasma ,Young Adult ,SDG 3 - Good Health and Well-being ,Pharmacokinetics ,Pregnancy ,medicine ,Humans ,Pharmacology (medical) ,Dosing ,education ,Pharmacology ,education.field_of_study ,Vaginal delivery ,business.industry ,Infant, Newborn ,Gestational age ,medicine.disease ,Anti-Bacterial Agents ,Infectious Diseases ,medicine.anatomical_structure ,Anesthesia ,Female ,business ,medicine.drug - Abstract
Background Intra-partum cefazolin is used to prevent group B Streptococcus (GBS) vertical transmission in mothers allergic to penicillin without a history of anaphylaxis. Objectives To investigate the maternal cefazolin dose–exposure relationship and subsequent maternal and neonatal target attainment at delivery. Methods Data were obtained from 24 healthy, GBS-colonized pregnant women (20–41 years), undergoing vaginal delivery (gestational age ≥37 weeks). During labour, all women received a 2 g cefazolin IV infusion. Eight hours later, eight women received another 1 g in the event of delayed (>8 h) delivery. Next to maternal plasma concentrations (up to 10 per dosing interval, until delivery), venous and arterial umbilical cord concentrations were determined at delivery. Target attainment in maternal/neonatal plasma was set at 1 mg/L for 60% of the dosing interval (unbound cefazolin, worst-case clinical breakpoint). A population pharmacokinetic (popPK) model was built (NONMEM 7.4). ClinicalTrials.gov Identifier: NCT01295606. Results At delivery, maternal blood and arterial umbilical cord unbound cefazolin concentrations were >1 mg/L in 23/24 (95.8%) and 11/12 (91.7%), respectively. The popPK of cefazolin in pregnant women was described by a two-compartment model with first-order elimination. Two additional compartments described the venous and arterial umbilical cord concentration data. Cefazolin target attainment was adequate in the studied cohort, where delivery occurred no later than 6.5 h after either the first or the second dose. PopPK simulations showed adequate maternal and umbilical cord exposure for 12 h following the first dose. Conclusions PopPK simulations showed that standard pre-delivery maternal cefazolin dosing provided adequate target attainment up to the time of delivery.
- Published
- 2021
15. Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease
- Author
-
Benadji, Amine, Danis, Kostas, Brieu, Nathalie, Gaillat, Jacques, Mourvillier, Bruno, Bollaert, Pierre-Edouard, Gaillot, Olivier, Taha, Muhamed-Kheir, Bonacorsi, Stephane, Lecuit, Marc, Frachet, Bruno, Debroucker, Thomas, Levy Bruhl, Daniel, Preau, Marie, Anguel, Nadia, Argaud, Laurent, Arista, Sophie, Armand-Lefevre, Laurence, Balavoine, Stéphanie, Baraduc, Régine, Barnaud, Guilène, Béraud, Guillaume, Bernars, Georges, Bertei, Dominique, Bessede, Emilie, Billard Pomares, Typhaine, Biron, Charlotte, Bland, Stéphane, Boileau, Julien, Boubeau, Patrice, Bourdon, Sandra, Bousquet, Aurore, Boyer, Sophie, Bozorg-Grayeli, Alexis, Bretonniere, Cédric, Bricaire, François, Brocas, Elsa, Brun, Michel, Buret, Jennifer, Burucoa, Christophe, Cabalion, Jean, Cabon, Mathieu, Cambau, Emmanuelle, Camuset, Guillaume, Canevet, Christophe, Caron, François, Carricajo, Anne, Castan, Bernard, Caumes, Eric, Cazanave, Charles, Chabrol, Amélie, Challan-Belval, Thibaut, Chanteperdrix-Marillier, Vanessa, Chaplain, Chantal, Charlier-Woerther, Caroline, Chaussade, Hélène, Chirouze, Catherine, Clair, Bernard, Colot, Julien, Conil, Jean-Marie, Cordel, Hugues, Cormier, Philippe, Cousson, Joël, Cronier, Pierrick, Cua, Eric, Dao-Dubremetz, Anne, Dargere, Sylvie, Degand, Nicolas, Dekeyser, Sophie, Delaune, Deborah, Denes, Eric, Dequin, Pierre-Francois, Descamps, Diane, Descloux, Elodie, Desmaretz, Jean-Luc, Diehl, Jean-Luc, Dimet, Jérôme, Dinh, Aurélien, Duval, Xavier, Escaut, Lelia, Fabe, Claude, Faibis, Frédéric, Flateau, Clara, Fonsale, Nathalie, Fortineau, Nicolas, Gagneux-Brunon, Amandine, Garandeau, Caroline, Garcia, Magali, Garot, Denis, Gaudry, Stéphane, Goehringer, François, Gravet, Alain, Gregoire-Faucher, Valérie, Grosset, Marine, Gueit, Isabelle, Guelon, Dominique, Guimard, Thomas, Hadou, Tahar, Helene, Jean-Pierre, Henard, Sandrine, Henry, Benoit, Hochart, Anne-Cécile, Hoen, Bruno, Illes, Gabriela, Jaffuel, Sylvain, Jarrin, Irène, Jaureguy, Françoise, Joseph, Cédric, Juvin, Marie-Emmanuelle, Kayal, Samer, Kerneis, Solen, Lamaury, Isabelle, Laurens, Etienne, Laurichesse, Henri, Le Brun, Cécile, Le Moing, Vincent, Le Turnier, Paul, Lecuyer, Hervé, Ledru, Sylvie, Legrix, Céline, Lemaignen, Adrien, Lemble, Chantal, Lemee, Ludovic, Lesens, Olivier, Lhommet, Claire, Males, Silvija, Malpote, Edith, Martin-Blondel, Guillaume, Marx, Matthieu, Masson, Raphael, Matray, Olivier, Mbadi, Aurore, Mechai, Frédéric, Mellon, Guillaume, Merens, Audrey, Meyohas, Marie Caroline, Michon, Adrien, Mootien Yoganaden, Joy, Morquin, David, Mouly, Stéphane, Mrozek, Natacha, Nguyen, Sophie, Oziol, Eric, Page, Bernard, Patrat-Delon, Solène, Patry, Isabelle, Picot, Sandrine, Pierrejean, Denys, Piroth, Lionel, Plassart, Claire, Plessis, Patrice, Ploy, Marie-Cécile, Portel, Laurent, Poubeau, Patrice, Poupard, Marie, Poyart, Claire, Prazuck, Thierry, Quaesaet, Luc, Raffi, François, Ramanantsoa, Adriatsiferana, Rapp, Christophe, Raskine, Laurent, Raymond, Josette, Revest, Matthieu, Riche, Agnès, Robaday-Voisin, Stéphanie, Robin, Frédéric, Romaszko, Jean-Pierre, Rousseau, Florence, Roux, Anne-Laure, Royer, Cécile, Saada, Matthieu, Salmon, Dominique, Saroufim, Carlo, Schmit, Jean Luc, Sebire, Manuela, Segonds, Christine, Sivadon-Tardy, Valérie, Soismier, Nathalie, Son, Olivia, Sunder, Simon, Suy, Florence, Tande, Didier, Tankovic, Jacques, Valin, Nadia, van Grunderbeeck, Nicolas, Vandenesch, François, Varon, Emmanuelle, Verdon, Renaud, Vergnaud, Michel, Vidal, Magali, Vittecoq, Daniel, Vuotto, Fanny, Gorenne, Isabelle, Laouenan, Cédric, Marcault, Estelle, Mentre, France, Pasquet, Blandine, Roy, Carine, Tubiana, Sarah, Arsac, Philippe, Benoit, Martha, Bernard, Louis, Bissuel, François, Bret, Laurent, Brieu, Natalie, Burret, Jennifer, Carvalhoschneider, Claudia, Champagne, Hélène, Chapalain, Joséphine, Chardon, Hubert, Chavanet, Pascal, Ducruet, Judith, Epaulard, Olivier, Fabre, Marc, Fasquelle, Dominique, Forestier, Emmanuel, Galempoix, Jean-Marc, Gautier, Guillaume, de Curraize, Claire Goulard, Gracet, Alain, Gubavu, Camélia, Guinard, Jérôme, Habet, Tarik, Haudour, Aurélie, Henry, Caroline, Hombrouckalet, Cécile, Janssen, Céline, Kisteman, Jean-Paul, Lanotte, Philippe, Lartigue, Marie-Frédérique, Launois, Claire, Lebrun, Cécile, Legout, Laurence, Levast, Marion, Madoux, Yannick, Maulin, Laurence, Mestrallet, Stéphanie, Mohareb, Abdo, Mootien, Joy, Nguyen, Yohan, Noel, Franck, Ogielska, Maja, Ogier Desserrey, Agathe, Paleau, Anne, Pavel, Simona, Pechinot, André, Pelloux, Isabelle, Petillon, Camille, Petitprez, Hélène, Podac, Bianca, Poirot, Jerome, Ponceau, Bénédicte, Prieur, Nathalie, Recule, Christine, Saraceni, Orlando, Sartre, Jacques, Sifaoui, Farid, Simonin, Catherine, Strady, Christophe, Tellini, Charlotte, Texier, Anthony, Thouvenin, Maxime, Tixier, Anne, Tremeaux, Pauline, Verger, Pascale, Vernet-Garnier, Véronique, Verquin, Jean-Pierre, Vitrat, Virginie, Vray, Isabelle, Zamfir, Oana, Zucchini, Laure, Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], CHI Créteil, Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), The COMBAT study was supported by the Assistance Publique Hopitaux de Paris, French Ministry of Health, Inserm, SPILF, and the Pfizer Pharmaceutical company, which also funded ORP. The study was endorsed by the following professional organizations: Association Pour l’enseignement de la Thérapeutique, Société de Pathologie Infectieuse de Langue Française, Société Française de Microbiologie, Société Nationale Française de Médecine Interne, Société de Réanimation de Langue Française, Société Française de Gérontologie, Société Française d’Anesthésie-Réanimation. The SIIP study was supported by (i) the Société de Pathologie Infectieuse de Langue Fran.aise (SPILF, the French Infectious Diseases Society), (ii) Santé Publique France (SpFrance, the French National Public Health Agency), (iii) the European Centre for Disease Prevention and Control (ECDC), and (iv) Pfizer. The Regional Observatories of Pneumococci (Observatoires Régionaux du Pneumocoque) were supported by Pfizer, BioMerieux, and Sanofi., and Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE)
- Subjects
Adult ,Microbiology (medical) ,Serotype ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,[SDV]Life Sciences [q-bio] ,30-day mortality ,Serogroup ,medicine.disease_cause ,Logistic regression ,Pneumococcal Infections ,Cohort Studies ,Pneumococcal Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Streptococcus pneumoniae ,medicine ,Humans ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,Aged ,0303 health sciences ,Meningitis, Pneumococcal ,030306 microbiology ,business.industry ,Mortality rate ,Infant ,Invasive pneumococcal disease ,Pneumococcal vaccine ,General Medicine ,bacterial infections and mycoses ,medicine.disease ,3. Good health ,Infectious Diseases ,business ,Meningitis ,Cohort study - Abstract
International audience; Purpose: Invasive pneumococcal disease (IPD) is responsible for substantial mortality and morbidity worldwide. We aimed to identify host and bacterial factors associated with 30-day mortality in 18-year-old patients hospitalized with IPD in France from 2013 to 2015.Methods: This study analyzed data collected from consecutives IPD cases included in two parallel multi-center cohort studies: COMBAT study (280 patients with pneumococcal community-acquired bacterial meningitis) and SIIP study (491 patients with non-meningitis IPD). Factors associated with 30-day mortality were identified using logistic regression.Results: Among the 771 enrolled patients (median age 66 years, IQR [52.0-79.7]), 592/767 (77.2%) had at least one chronic disease. Patients with meningitis were younger (60.2 vs 70.9 years; p < 0.001) and had fewer chronic diseases than those with non-meningitis IPD (73.3% vs 79.4%; p = 0.05). Non-vaccine serotypes were more frequent in meningitis patients than in those with other IPD (36.1% vs 23.1%; p < 0.001). The overall 30-day mortality was 16.7% and patients with concurrent meningitis and extra-cerebral IPD had the highest 30-day mortality rate (26.5%). On multivariate analyses, older age, history of malignant solid tumor, meningeal IPD and serotypes previously identified with high mortality potential were independently associated with 30-day mortality. Of the serotypes with high mortality potential, 80% were included in licensed (PCV13 or PPV23) vaccines.Conclusion: We observed an effect of both host factors and pneumococcal serotypes on 30-day mortality in IPD. This highlights the need for a focused strategy to vaccinate at-risk patients.Clinical trial: ClinicalTrial. Gov identification number: NCT01730690.
- Published
- 2021
16. Validation of a French-language version of TeamSTEPPS® T-TPQ and T-TAQ questionnaires
- Author
-
Méryl Paquay, Nadia Dardenne, Laure Istas, Pauline Van Ngoc, Anne-Françoise Donneau, Alexandre Ghuysen, Jean-Christophe Servotte, Anh Nguyet Diep, and Mathilde Charlier
- Subjects
Teamwork ,Psychometrics ,030504 nursing ,Attitude of Health Personnel ,Leadership Scale ,Intraclass correlation ,Interprofessional Relations ,media_common.quotation_subject ,Applied psychology ,Discriminant validity ,Reproducibility of Results ,Context (language use) ,General Medicine ,Confirmatory factor analysis ,03 medical and health sciences ,0302 clinical medicine ,Cronbach's alpha ,Surveys and Questionnaires ,Humans ,030212 general & internal medicine ,0305 other medical science ,Psychology ,Reliability (statistics) ,Language ,media_common - Abstract
Teamwork training and evaluation are essential to enhance safety and quality of care. The lack of the psychometric testing of the TeamSTEPPS® Teamwork Attitudes Questionnaire (T-TAQ) and Teamwork Perceptions Questionnaire (T-TPQ) across different language and cultural settings has questioned their widespread use because such attitudes and perceptions are highly subjective and context-bound. The present study aims to translate the T-TAQ and T-TPQ into the French language and validate the psychometric properties of the two questionnaires in a public health context. A forward-backward translation process, panel reviewing, and pilot testing in two rounds were followed to develop the French versions. Confirmatory factor analysis (CFA) and Cronbach's alpha were used to examine the factor structure and internal consistency, whereas two-way mixed Intraclass Correlation Coefficient (ICC) was performed to assess test-retest reliability. A total of 235 healthcare professionals in the French-speaking community of Belgium completed the T-TAQ and T-TPQ. After two to four weeks, 102 participants took part in the second round. Despite good fit indices as revealed by the CFA and Cronbach's alpha from 0.53 to 0.75 for the five dimensions of the T-TAQ and 0.76 to 0.79 for the T-TPQ, the squared correlations among the constructs were higher than the average variance extracted. Two-way mixed ICCs indicated fair to good test-retest reliability for all the five constructs of the two questionnaires, except the leadership scale of the T-TAQ. The French-language versions of the T-TAQ and T-TPQ were semantically equivalent and culturally relevant with adequate test-retest reliability as compared to the English versions. These two instruments might be used to capture the overall attitude toward teamwork and perceptions of team skills and behaviors. Yet, further research is advisable to refine the scales to establish the discriminant validity of the different dimensions and discriminative power of the instruments.
- Published
- 2021
17. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces
- Author
-
Delphine Lapaillerie, Cathy Charlier, Véronique Guyonnet-Dupérat, Emilie Murigneux, Henrique S. Fernandes, Fábio G. Martins, Rita P. Magalhães, Tatiana F. Vieira, Clémence Richetta, Frédéric Subra, Samuel Lebourgeois, Charlotte Charpentier, Diane Descamps, Benoît Visseaux, Pierre Weigel, Alexandre Favereaux, Claire Beauvineau, Frédéric Buron, Marie-Paule Teulade-Fichou, Sylvain Routier, Sarah Gallois-Montbrun, Laurent Meertens, Olivier Delelis, Sérgio F. Sousa, Vincent Parissi, Microbiologie Fondamentale et Pathogénicité (MFP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Unité en Sciences Biologiques et Biotechnologies de Nantes (US2B), Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), TBM-Core [Bordeaux] (UMS3427 - INSERM US005), Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Universidade do Porto = University of Porto, Laboratoire de biologie et pharmacologie appliquée (LBPA), Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Ecole Normale Supérieure Paris-Saclay (ENS Paris Saclay), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Interdisciplinary Institute for Neuroscience [Bordeaux] (IINS), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Chimie et modélisation pour la biologie du cancer (CMBC), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie Organique et Analytique (ICOA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité en Sciences Biologiques et Biotechnologies de Nantes - UMR CNRS 6286 (US2B), Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), TBM-Core [Bordeaux] (CNRS UMS 3427 - INSERM US 005), and delelis, olivier
- Subjects
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Pharmacology ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Pyridines ,SARS-CoV-2 ,[CHIM.THER] Chemical Sciences/Medicinal Chemistry ,ACE2 ,COVID-19 ,spike ,[CHIM.THER]Chemical Sciences/Medicinal Chemistry ,Peptidyl-Dipeptidase A ,Virus Internalization ,COVID-19 Drug Treatment ,inhibitor ,Molecular Docking Simulation ,Infectious Diseases ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Spike Glycoprotein, Coronavirus ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Humans ,Pharmacology (medical) ,viral entry ,Angiotensin-Converting Enzyme 2 ,Protein Binding - Abstract
International audience; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent that has caused the current coronavirus disease (COVID) pandemic. Viral infection relies on the viral S (spike) protein/cellular receptor ACE2 interaction. Disrupting this interaction would lead to early blockage of viral replication. To identify chemical tools to further study these functional interfaces, 139,146 compounds from different chemical libraries were screened through an S/ACE2 in silico virtual molecular model. The best compounds were selected for further characterization using both cellular and biochemical approaches, reiterating SARS-CoV-2 entry and the S/ACE2 interaction. We report here two selected hits, bis-indolyl pyridine AB-00011778 and triphenylamine AB-00047476. Both of these compounds can block the infectivity of lentiviral vectors pseudotyped with the SARS-CoV-2 S protein as well as wild-type and circulating variant SARS-CoV-2 strains in various human cell lines, including pulmonary cells naturally susceptible to infection. AlphaLISA and biolayer interferometry confirmed a direct inhibitory effect of these drugs on the S/ACE2 association. A specific study of the AB-00011778 inhibitory properties showed that this drug inhibits viral replication with a 50% effective concentration (EC 50) between 0.1 and 0.5 mM depending on the cell lines. Molecular docking calculations of the interaction parameters of the molecules within the S/ACE2 complex from both wild-type and circulating variants of the virus showed that the molecules may target multiple sites within the S/ACE2 interface. Our work indicates that AB-00011778 constitutes a good tool for modulating this interface and a strong lead compound for further therapeutic purposes.
- Published
- 2022
18. Biochip array technology for new psychoactive substances detection in biological samples: Evaluation of the specificity of the Randox Evidence Investigator
- Author
-
Marine Deville, Ronald Bailly, Nicolas Gauthier, Pauline Pitti, Audrey Wachtelaer, and Corinne Charlier
- Subjects
Fentanyl ,Substance Abuse Detection ,Benzodiazepines ,Technology ,Cannabinoids ,Opiate Alkaloids ,Clinical Biochemistry ,Acetamides ,Humans ,General Medicine ,Clonazepam ,Piperazines - Abstract
Background The need to detect new psychoactive substances in biological samples is of crucial interest. In this paper, the specificity of a benchtop immunoanalyzer commercialized by Randox was evaluated on real patient samples. Method The Evidence Investigator was assessed to screen for NPS on 80 serum and urine samples coming from patients admitted to the emergency department. Targeted NPS were included in various categories such as synthetic cannabinoids, opioids and benzodiazepines. Results were compared with a chromatographic technique coupled with mass spectrometry. Results No NPS was detected by the reference technique. Concerning immunoanalysis, some piperazines were positive, caused by the presence of medicine containing this chemical structure. Clonazepam and fentanyl derivatives were confirmed in some cases, but sometimes the positivity was explained by other opiates or benzodiazepines, which also explained two samples falsely positive for etizolam. Conclusions The Randox Evidence Investigator was rapid and easy to use. It can be used as a first intention but always followed by a more specific technique in order to detect false positive result.
- Published
- 2022
19. Tribal makeup painting mimicking achromic lupus in a Teke tribal chef: icono-diagnosis is a dangerous art
- Author
-
Phillipe Charlier, Nicolas Kluger, and Virginie Bourdin
- Subjects
Hypopigmentation ,Vitiligo ,Humans ,Dermatology - Abstract
A close-up photograph of a Teke community Chief (Congo, circa 1880–1890) seemed to be of diagnostic interest, as areas of achromic maculae were visible on the hands: the most relevant diagnoses were a Koebner phenomenon on a background of vitiligo, or a diagnosis of lupus. However, examination of the entire photograph showed that the ‘maculae’ were in fact tribal makeup, showing the methodological limits of icono-diagnosis.
- Published
- 2022
20. One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study
- Author
-
Duval, Xavier, Taha, Muhamed-Kheir, Lamaury, Isabelle, Escaut, Lélia, Gueit, Isabelle, Manchon, Pauline, Tubiana, Sarah, Hoen, Bruno, Mourvillier, Bruno, Ploy, Marie-Cécile, Varon, Emmanuelle, Caron, François, Bollaert, Pierre-Edouard, Gaillot, Olivier, Poyart, Claire, Bonacorsi, Stephane, Vandenesch, François, Cambau, Emmanuelle, Lecuit, Marc, Gravet, Alain, Frachet, Bruno, de Broucker, Thomas, Bruhl, Daniel Levy, Raffi, François, Preau, Marie, Anguel, Nadia, Argaud, Laurent, Arista, Sophie, Armand-Lefevre, Laurence, Balavoine, Stéphanie, Baraduc, Régine, Barnaud, Guilène, Beraud, Guillaume, Bernard, Louis, Bernars, Georges, Bertei, Dominique, Bessede, Emilie, Pomares, Typhaine Billard, Biron, Charlotte, Bland, Stéphane, Boileau, Julien, Boubeau, Patrice, Bourdon, Sandra, Bousquet, Aurore, Boyer, Sophie, Bozorg-Grayeli, Alexis, Bret, Laurent, Bretonniere, Cédric, Bricaire, François, Brocas, Elsa, Brun, Michel, Buret, Jennifer, Burucoa, Christophe, Cabalion, Jean, Cabon, Mathieu, Camuset, Guillaume, Canevet, Christophe, Carricajo, Anne, Castan, Bernard, Caumes, Eric, Cazanave, Charles, Chabrol, Amélie, Challan-Belval, Thibaut, Chanteperdrix-Marillier, Vanessa, Chaplain, Chantal, Charlier-Woerther, Caroline, Chaussade, Hélène, Chirouze, Catherine, Clair, Bernard, Colot, Julien, Conil, Jean-Marie, Cordel, Hugues, Cormier, Philippe, Cousson, Joël, Cronier, Pierrick, Cua, Eric, Dao-Dubremetz, Anne, Dargere, Sylvie, Degand, Nicolas, Dekeyser, Sophie, Delaune, Deborah, Denes, Eric, Dequin, Pierre-Francois, Descamps, Diane, Descloux, Elodie, Desmaretz, Jean-Luc, Diehl, Jean-Luc, Dimet, Jérôme, Duval, Aurélien Dinh Xavier, Fabe, Claude, Faibis, Frédéric, Flateau, Clara, Fonsale, Nathalie, Forestier, Emmanuel, Fortineau, Nicolas, Gagneux-Brunon, Amandine, Garandeau, Caroline, Garcia, Magali, Garot, Denis, Gaudry, Stéphane, Goehringer, François, Gregoire-Faucher, Valérie, Grosset, Marine, Gubavu, Camélia, Guelon, Dominique, Guimard, Thomas, Guinard, Jérôme, Hadou, Tahar, Helene, Jean-Pierre, Henard, Sandrine, Henry, Benoit, Hochart, Anne-Cécile, Illes, Gabriela, Jaffuel, Sylvain, Jarrin, Irène, Jaureguy, Françoise, Joseph, Cédric, Juvin, Marie-Emmanuelle, Kayal, Samer, Kerneis, Solen, Lacassin, Flore, Lanotte, Philippe, Laurens, Etienne, Laurichesse, Henri, Le Brun, Cécile, Le Moing, Vincent, Le Turnier, Paul, Lecuyer, Hervé, Ledru, Sylvie, Legrix, Céline, Lemaignen, Adrien, Lemble, Chantal, Lemee, Ludovic, Lesens, Olivier, Levast, Marion, Lhommet, Claire, Males, Silvija, Malpote, Edith, Martin-Blondel, Guillaume, Marx, Matthieu, Masson, Raphael, Matray, Olivier, Mbadi, Aurore, Mechai, Frédéric, Mellon, Guillaume, Merens, Audrey, Meyohas, Marie Caroline, Michon, Adrien, Yoganaden, Joy Mootien, Morquin, David, Mouly, Stéphane, Mrozek, Natacha, Nguyen, Sophie, Nguyen, Yohan, Ogielska, Maja, Oziol, Eric, Page, Bernard, Patrat-Delon, Solène, Patry, Isabelle, Pechinot, André, Picot, Sandrine, Pierrejean, Denys, Piroth, Lionel, Plassart, Claire, Plessis, Patrice, Portel, Laurent, Poubeau, Patrice, Poupard, Marie, Prazuck, Thierry, Quaesaet, Luc, Ramanantsoa, Adriatsiferana, Rapp, Christophe, Raskine, Laurent, Raymond, Josette, Revest, Matthieu, Riche, Agnès, Robaday-Voisin, Stéphanie, Robin, Frédéric, Romaszko, Jean-Pierre, Rousseau, Florence, Roux, Anne-Laure, Royer, Cécile, Saada, Matthieu, Salmon, Dominique, Saroufim, Carlo, Schmit, Jean Luc, Sebire, Manuela, Segonds, Christine, Sivadon-Tardy, Valérie, Soismier, Nathalie, Son, Olivia, Sunder, Simon, Suy, Florence, Tande, Didier, Tankovic, Jacques, Valin, Nadia, van Grunderbeeck, Nicolas, Verdon, Renaud, Vergnaud, Michel, Vernet-Garnier, Véronique, Vidal, Magali, Vitrat, Virginie, Vittecoq, Daniel, Vuotto, Fanny, Gorenne, Isabelle, Laouenan, Cédric, Marcault, Estelle, Mentre, France, Pasquet, Blandine, Roy, Carine, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Infections Bactériennes Invasives - Invasive Bacterial Infections, Institut Pasteur [Paris] (IP), CHU Pointe-à-Pitre/Abymes [Guadeloupe], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), CHU Rouen, Normandie Université (NU), and This study was supported by funding from the Assistance Publique Hopitaux de Paris, the French Society of Infectious Diseases, Pfizer and Sanofi. The rapid service and open access fees were funded by Sanofi.
- Subjects
Adult ,Community-acquired bacterial meningitis ,Adolescent ,[SDV]Life Sciences [q-bio] ,General Medicine ,Meningitis, Meningococcal ,Meningococcal meningitis ,Meningitis, Bacterial ,Cohort Studies ,Disease Progression ,Quality of Life ,Humans ,Pharmacology (medical) ,Prospective Studies ,France ,Long-term follow-up - Abstract
Trial registration: ClinicalTrial.Gov identification number NCT01730690. the COMBAT study group; International audience; Introduction: COMBAT is a prospective, multicentre cohort study that enrolled consecutive adults with community-acquired bacterial meningitis (CABM) in 69 participating centres in France between February 2013 and July 2015 and followed them for 1 year.Methods: Patients aged at least 18 years old, hospitalised with CABM were followed during their hospitalisation and then contacted by phone 12 months after enrolment. Here we present the prevalence of sequelae at 12 months in a subgroup of patients with meningococcal meningitis.Results: Five of the 111 patients with meningococcal meningitis died during initial hospitalisation and two died between discharge and 12 months, leaving 104 patients alive 1 year after enrolment, 71 of whom provided 12-month follow-up data. The median age was 30.0 years and 54.1% of the patients had no identified risk factor for meningitis. More than 30% reported persistent headache, more than 40% were not satisfied with their sleep and 10% had concentration difficulties. Hearing loss was present in about 15% of the patients and more than 30% had depressive symptoms. About 13% of the patients with a previous professional activity had not resumed work. On the SF-12 Health Survey, almost 50% and 30% had physical component or mental component scores lower than the 25th percentile of the score distribution in the French general population. There was a non-significant improvement in the patients' disability scores from hospital discharge to 12 months (p = 0.16), but about 10% of the patients had residual disability.Conclusions: Although most patients in our cohort survive meningococcal meningitis, the long-term burden is substantial and therefore it is important to ensure a prolonged follow-up of survivors and to promote preventive strategies, including vaccination.
- Published
- 2022
21. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
- Author
-
Yann Nguyen, Adrien Flahault, Nathalie Chavarot, Cléa Melenotte, Morgane Cheminant, Paul Deschamps, Nicolas Carlier, Emmanuel Lafont, Marion Thomas, Edouard Flamarion, David Lebeaux, Caroline Charlier, Anne Rachline, Corinne Guérin, Robert Ratiney, Justine Touchard, Hélène Péré, Flore Rozenberg, Fanny Lanternier, Jean-Benoît Arlet, Jérôme Avouac, Véronique Boussaud, Romain Guillemain, Marguerite Vignon, Eric Thervet, Anne Scemla, Laurence Weiss, and Luc Mouthon
- Subjects
Microbiology (medical) ,Cohort Studies ,Immunocompromised Host ,Infectious Diseases ,SARS-CoV-2 ,Humans ,COVID-19 ,Antibodies, Monoclonal ,Pre-Exposure Prophylaxis ,General Medicine ,COVID-19 Drug Treatment - Abstract
Immunocompromised patients have an increased risk of a severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis during the Omicron wave in France.This was an observational multicentre cohort study of immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis between December 28, 2021 and March 31, 2022. Patients received tixagevimab/cilgavimab 150/150 mg intramuscularly if they had impaired vaccine response and a high risk of severe form of COVID-19.Tixagevimab/cilgavimab was administered to 1112 immunocompromised patients. After a median (range) follow-up of 63 (49-73) days, COVID-19 was confirmed in 49/1112 (4.4%) ≥5 days after treatment. During the study period, mean weekly incidence rate was 1669 in 100 000 inhabitants in Ile-de-France and 530 in 100 000 among patients who received tixagevimab/cilgavimab prophylaxis. Among infected patients, 43/49 (88%) had a mild-to-moderate form and 6/49 (12%) had a moderate-to-severe form of COVID-19. Patients with moderate-to-severe illnesses were less likely to have received early therapies than patients with mild forms (53.5% vs. 16.7% respectively) and 2/49 (4%) patients died from COVID-19.Our study reported a low rate of infections and severe illnesses among immunocompromised patients treated with tixagevimab/cilgavimab. A global preventive strategy including vaccines, preexposure prophylaxis with monoclonal antibodies, and early therapies might be effective to prevent severe forms of COVID-19 among severely immunocompromised patients.
- Published
- 2022
22. Urinary levels of parabens, phthalate metabolites, bisphenol A and plasticizer alternatives in a Belgian population: Time trend or impact of an awareness campaign?
- Author
-
Catherine Pirard and Corinne Charlier
- Subjects
Adult ,Belgium ,Phenols ,Plasticizers ,Phthalic Acids ,Humans ,Parabens ,Environmental Pollutants ,Environmental Exposure ,Benzhydryl Compounds ,Biochemistry ,General Environmental Science - Abstract
A human biomonitoring study was carried out in 2015 within an adult population living in Liege (Belgium). Some phthalate metabolites and parabens were measured in the urine of 252 participants, and information were collected about their food habits, life styles and home environment to identify some predictors of exposure. Concomitantly, an awareness campaign was initiated by the Provincial Authorities of Liege and spread over 2 years. Three years later (2018), 92 of the initial participants provided again urine samples, and the levels of phthalate metabolites, phthalate substitute (DINCH), parabens, bisphenol-A and bisphenol alternatives (bisphenol-S, -F, -Z, -P) were determined and compared to those obtained in 2015 to assess time trends. In 2015, methyl- and ethylparaben were the most abundant parabens (P50 = 9.12 μg/L and 1.1 μg/L respectively), while propyl- and butylparaben were sparsely detected. Except for mono-2-ethylhexyl phthalate and 6-OH-mono-propyl-heptyl phthalate, all other targeted phthalate metabolites were positively quantified in most of the urine samples (between 89 and 98%) with median concentrations ranging between 2.7 μg/L and 21.3 μg/L depending on the metabolite. The multivariate regression models highlighted some significant associations between urinary phthalate metabolite or paraben levels and age, rural or urban character of the residence place, and the use of some personal care products. However, all determination coefficients were weak meaning that the usual covariates included in the models only explained a small part of the variance. Between 2015 and 2018, levels of parabens and phthalate metabolites significantly decreased (from 1.3 to 2.5 fold) except for monoethyl phthalate which seemed to remain quite constant. Contrariwise, all bisphenol alternatives and DINCH metabolites were measured in higher concentrations in 2018 vs 2015 while BPA levels did not differ significantly. However, it was not feasible to unequivocally highlight an impact of the awareness campaign on the exposure levels of the population.
- Published
- 2022
23. Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program
- Author
-
Chirayu Goswami, Michael Sheldon, Christian Bixby, Mehdi Keddache, Alexander Bogdanowicz, Yihe Wang, Jonathan Schultz, Jessica McDevitt, James LaPorta, Elaine Kwon, Steven Buyske, Dana Garbolino, Glenys Biloholowski, Alex Pastuszak, Mary Storella, Amit Bhalla, Florence Charlier-Rodriguez, Russ Hager, Robin Grimwood, and Shareef A. Nahas
- Subjects
Infectious Diseases ,SARS-CoV-2 ,COVID-19 ,Humans ,Genomics ,Centers for Disease Control and Prevention, U.S ,United States - Abstract
Background The Centers for Disease Control and Prevention contracted with laboratories to sequence the SARS-CoV-2 genome from positive samples across the United States to enable public health officials to investigate the impact of variants on disease severity as well as the effectiveness of vaccines and treatment. Herein we present the initial results correlating RT-PCR quality control metrics with sample collection and sequencing methods from full SARS-CoV-2 viral genomic sequencing of 24,441 positive patient samples between April and June 2021. Methods RT-PCR confirmed (N Gene Ct value Results An association was observed between higher sequencing coverage, quality, and samples with a lower Ct value, with 99% of positives sequenced was Omicron. Conclusion These initial analyses highlight the importance of sequencing platform, sample collection methods, and RT-PCR Ct values in guiding surveillance efforts. These surveillance studies evaluating genetic changes of SARS-CoV-2 have been identified as critical by the CDC that can affect many aspects of public health including transmission, disease severity, diagnostics, therapeutics, and vaccines.
- Published
- 2022
24. Impact of Blood Sampling on Anemia in the PICU: A Prospective Cohort Study
- Author
-
Tine François, Michaël Sauthier, Julien Charlier, Jessica Dessureault, Marisa Tucci, Karen Harrington, Laurence Ducharme-Crevier, Sally Al Omar, Jacques Lacroix, and Geneviève Du Pont-Thibodeau
- Subjects
Hemoglobins ,Sepsis ,Pediatrics, Perinatology and Child Health ,Humans ,Infant ,Anemia ,Prospective Studies ,Critical Care and Intensive Care Medicine ,Child ,Intensive Care Units, Pediatric ,Retrospective Studies - Abstract
Fifty percent of children are anemic after a critical illness. Iatrogenic blood testing may be a contributor to this problem. The objectives of this study were to describe blood sampling practice in a PICU, determine patient factors associated with increased sampling, and examine the association among blood sampling volume, anemia at PICU discharge, and change in hemoglobin from PICU entry to PICU discharge.Prospective observational cohort study.PICU of Sainte-Justine University Hospital.All children consecutively admitted during a 4-month period.Four hundred twenty-three children were enrolled. Mean blood volume sampled was 3.9 (±19) mL/kg/stay, of which 26% was discarded volume. Children with central venous or arterial access were sampled more than those without access (p0.05). Children with sepsis, shock, or cardiac surgery were most sampled, those with a primary respiratory diagnosis; the least (p0.001). We detected a strong association between blood sample volume and mechanical ventilation (H, 81.35; p0.0001), but no association with severity of illness (Worst Pediatric Logistic Organ Dysfunction score) (R, -0.044; p = 0.43). Multivariate analysis (n = 314) showed a significant association between the volume of blood sampled (as continuous variable) and anemia at discharge (adjusted OR, 1.63; 95% CI, 1.18-2.45; p = 0.003). We lacked power to detect an association between blood sampling and change in hemoglobin from PICU admission to PICU discharge.Diagnostic blood sampling in PICU is associated with anemia at discharge. Twenty-five percent of blood losses from sampling is wasted. Volumes are highest for patients with sepsis, shock, or cardiac surgery, and in patients with vascular access or ventilatory support.
- Published
- 2022
25. From Molière to SARS-CoV-2: How Medicine has changed
- Author
-
A. Perciaccante, P. Charlier, V. Asensi, S.T. Donell, A.G. Nerlich, and R. Bianucci
- Subjects
SARS-CoV-2 ,Gastroenterology ,Internal Medicine ,COVID-19 ,Humans ,Medicine - Published
- 2022
26. A transactional stress theory of global work demands: A challenge, hindrance, or both?
- Author
-
Maria L. Kraimer, Margaret A. Shaffer, Mark C. Bolino, Steven D. Charlier, and Olivier Wurtz
- Subjects
Family Conflict ,Surveys and Questionnaires ,Humans ,Burnout, Professional ,Applied Psychology - Abstract
We integrate research on global work demands (Shaffer et al., 2012) with transactional stress theory to examine both the harmful and beneficial effects of three global work demands-international travel, cognitive flexibility, and nonwork disruption-for employees engaged in global work. We propose that global work demands have indirect, and conditional, effects on burnout and work-to-family conflict (WFC), as well as thriving and work-family enrichment, through employees' appraisals that their global work is both hindering and challenging, respectively. We tested the hypotheses with a matched sample of 229 global employees and their spouses. We found that cognitive flexibility demands are related to harmful and beneficial outcomes: It increases WFC through hindrance appraisals of the global work, but also increases thriving through challenge appraisals. In comparison, international travel demands have only beneficial outcomes, such that it positively related to employee thriving through challenge appraisals, but only among employees working in jobs that have fewer nonwork disruption demands. Finally, nonwork disruption demands had only harmful effects in that it positively related to burnout and WFC through hindrance appraisals. Exploratory analyses also revealed that nonwork disruption demands negatively related to employee thriving, through challenge appraisals, when employees experienced
- Published
- 2022
27. Antimicrobial stewardship in high-risk febrile neutropenia patients
- Author
-
Adrien Contejean, Salam Abbara, Ryme Chentouh, Sophie Alviset, Eric Grignano, Nabil Gastli, Anne Casetta, Lise Willems, Etienne Canouï, Caroline Charlier, Frédéric Pène, Julien Charpentier, Jeanne Reboul-Marty, Rui Batista, Didier Bouscary, Solen Kernéis, UFR Médecine [Santé] - Université Paris Cité (UFR Médecine UPCité), Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Epidémiologie et modélisation de la résistance aux antimicrobiens - Epidemiology and modelling of bacterial escape to antimicrobials (EMAE), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Biologie des Infections - Biology of Infection, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, HAL UVSQ, Équipe, and Université Paris Cité - UFR Médecine [Santé] (UPCité UFR Médecine)
- Subjects
Microbiology (medical) ,Public Health, Environmental and Occupational Health ,Middle Aged ,Antimicrobial stewardship ,Prognosis ,Anti-Bacterial Agents ,Infectious Diseases ,Carbapenems ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Humans ,Antibiotic consumption ,Pharmacology (medical) ,Febrile Neutropenia ,Retrospective Studies ,High-risk febrile neutropenia - Abstract
Background The 2011 4th European Conference on Infections in Leukemia (ECIL4) guidelines recommend antibiotics de-escalation/discontinuation in selected febrile neutropenia (FN) patients. We aimed to assess the impact of an antimicrobial stewardship (AMS) program based on these guidelines on antibiotics use and clinical outcomes in high-risk FN patients. Methods We conducted an observational study in the hematology department of Cochin University Hospital in Paris, France. An ECIL4-based antibiotics de-escalation and discontinuation strategy was implemented jointly by the hematologists and the AMS team. The pre-intervention (January–October 2018) and post-intervention (January-October 2019) periods were compared. We retrospectively collected clinical and microbiological data. We compiled antibiotics consumptions via hospital pharmacy data and standardized them by calculating defined daily doses per 1000 patient-days. We analyzed the two-monthly antibiotic consumption using an interrupted time series method and built a composite endpoint for clinical outcomes based on transfer to the intensive care unit (ICU) and/or hospital death. Results Overall, 273 hospital stays (164 patients) in the pre-intervention and 217 (148 patients) in the post-intervention periods were analyzed. Patients were mainly hospitalized for intensive chemotherapy for acute leukemia or autologous stem-cell transplant for myeloma. Patients were slightly younger in the pre-intervention compared to the post-intervention period (median age 60.4 vs 65.2 years, p = 0.049), but otherwise comparable. After implementation of the AMS program, glycopeptide and carbapenem use decreased by 85% (p = 0.03) and 72% (p = 0.04), respectively. After adjustment on confounders, the risk of transfer to the ICU/death decreased significantly after implementation of the AMS program (post-intervention period: odds-ratio = 0.29, 95% Confidence Interval: 0.15–0.53, p Conclusion Implementation of a multidisciplinary AMS program for high-risk neutropenic patients was associated with lower carbapenem and glycopeptide use and improved clinical outcomes.
- Published
- 2022
28. War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
- Author
-
Antonio Perciaccante, Victor Asensi, Andrei I. Cucu, Philippe Charlier, Simon T. Donell, Andreas G. Nerlich, and Raffaella Bianucci
- Subjects
Europe ,Refugees ,Infectious Diseases ,General Veterinary ,General Immunology and Microbiology ,Vaccination ,Public Health, Environmental and Occupational Health ,Molecular Medicine ,Humans ,Pandemics - Published
- 2022
29. Analytical performance of eight enzymatic assays for ethanol in serum evaluated by data from the Belgian external quality assessment scheme
- Author
-
Wim Coucke, Corinne Charlier, Kathleen Croes, Boris Mahieu, Hugo Neels, Christophe Stove, Jan Tytgat, André Vanescote, Alain G. Verstraete, Sarah Wille, and Arnaud Capron
- Subjects
Belgium ,Ethanol ,Biochemistry (medical) ,Clinical Biochemistry ,Humans ,General Medicine ,Human medicine ,Enzyme Assays - Abstract
Objectives Fast and reliable ethanol assays analysis are used in a clinical context for patients suspected of ethanol intoxication. Mostly, automated systems using an enzymatic reaction based on ethanol dehydrogenase are used. The manuscript focusses on the evaluation of the performance of these assays. Methods Data included 30 serum samples used in the Belgian EQA scheme from 2019 to 2021 and concentrations ranged from 0.13 to 3.70 g/L. A regression line between target concentrations and reported values was calculated to evaluate outliers, bias, variability and measurement uncertainty. Results A total of 1,611 results were taken into account. Bias was the highest for Alinity c over the whole concentration range and the lowest for Vitros for low concentrations and Cobas 8000 using the c702 module for high concentrations. The Architect and Cobas c501/c502 systems showed the lowest variability over the whole concentration range. Highest variability was observed for Cobas 8000 using the 702 module, Thermo Scientific and Alinity c. Cobas 8000 using the c702 module showed the highest measurement uncertainty for lower concentrations. For higher concentrations, Alinity c, Thermo Scientific and Vitros were the methods with the highest measurement uncertainty. Conclusions The bias of the enzymatic techniques is nearly negligible for all methods except Alinity c. Variability differs strongly between measurement procedures. This study shows that the Alinity c has a worse measurement uncertainty than other systems for concentrations above 0.5 g/L. Overall, we found the differences in measurement uncertainty to be mainly influenced by the differences in variability.
- Published
- 2022
30. Speech-Language Pathologists' Support for Parents of Young d/Deaf Multilingual Learners
- Author
-
Pauline van der Straten Waillet, Cécile Colin, Kathryn Crowe, and Brigitte Charlier
- Subjects
Parents ,Pathologists ,Speech and Hearing ,Persons With Hearing Impairments ,Speech-Language Pathology ,Communication Disorders ,Humans ,Speech ,Multilingualism ,Cultural Diversity ,Child ,Education - Abstract
Increasing cultural and linguistic diversity among children and families brings new challenges for early intervention professionals. The purpose of this study was to identify the specific roles and needs of speech-language pathologists (SLPs) who practice in early intervention settings with culturally and linguistically diverse families of d/Deaf multilingual learners (DMLs). Thirteen SLPs completed an online survey about their practices and needs. Interviews were conducted with five parents of DMLs. Results showed that SLPs have lower self-satisfaction with families of DMLs compared to mainstream families. Parents were highly satisfied with the support they received. Both groups of participants reported a need for specific tools or adaptations, especially if there was no shared language. Thematic analysis identified three themes: communication and partnership, professional resources for responding to diversity, and diversity of parental profiles. This article provides an insight into the perspectives of both professionals and culturally and linguistically diverse parents, and identifies specific aspects of early intervention services with parents of DMLs: developing partnership in the context of cultural and/or linguistic differences, discussing topics related to multilingualism, and providing highly adaptable family-centered services.
- Published
- 2022
31. A DNA repair-independent role for alkyladenine DNA glycosylase in alkylation-induced unfolded protein response
- Author
-
Larissa Milano, Clara F. Charlier, Rafaela Andreguetti, Thomas Cox, Eleanor Healing, Marcos P. Thomé, Ruan M. Elliott, Leona D. Samson, Jean-Yves Masson, Guido Lenz, João Antonio P. Henriques, Axel Nohturfft, and Lisiane B. Meira
- Subjects
X-Box Binding Protein 1 ,Multidisciplinary ,Alkylation ,DNA Repair ,Brain Neoplasms ,Endoplasmic Reticulum Stress ,female genital diseases and pregnancy complications ,DNA Glycosylases ,Mice ,polycyclic compounds ,Animals ,Humans ,Glioblastoma ,Protein Unfolding - Abstract
Alkylating agents damage DNA and proteins and are widely used in cancer chemotherapy. While cellular responses to alkylation-induced DNA damage have been explored, knowledge of how alkylation affects global cellular stress responses is sparse. Here, we examined the effects of the alkylating agent methylmethane sulfonate (MMS) on gene expression in mouse liver, using mice deficient in alkyladenine DNA glycosylase (Aag), the enzyme that initiates the repair of alkylated DNA bases. MMS induced a robust transcriptional response in wild-type liver that included markers of the endoplasmic reticulum (ER) stress/unfolded protein response (UPR) known to be controlled by XBP1, a key UPR effector. Importantly, this response is significantly reduced in the Aag knockout. To investigate how AAG affects alkylation-induced UPR, the expression of UPR markers after MMS treatment was interrogated in human glioblastoma cells expressing different AAG levels. Alkylation induced the UPR in cells expressing AAG; conversely, AAG knockdown compromised UPR induction and led to a defect in XBP1 activation. To verify the requirements for the DNA repair activity of AAG in this response, AAG knockdown cells were complemented with wild-type Aag or with an Aag variant producing a glycosylase-deficient AAG protein. As expected, the glycosylase-defective Aag does not fully protect AAG knockdown cells against MMS-induced cytotoxicity. Remarkably, however, alkylation-induced XBP1 activation is fully complemented by the catalytically inactive AAG enzyme. This work establishes that, besides its enzymatic activity, AAG has noncanonical functions in alkylation-induced UPR that contribute to cellular responses to alkylation.
- Published
- 2022
32. Vaccination as a nativity scene
- Author
-
Antonio Perciaccante, Victor Asensi, Philippe Charlier, Simon T. Donell, Andreas G. Nerlich, and Raffaella Bianucci
- Subjects
Vaccination ,Emergency Medicine ,Internal Medicine ,Emigrants and Immigrants ,Humans ,Healthcare Disparities - Published
- 2022
33. Risk of groundwater contamination widely underestimated because of fast flow into aquifers
- Author
-
E. Zagana, Juan Antonio Barberá, Christine Stumpp, Damián Sánchez, José Francisco Martín, Martin Kralik, Jens Lange, Bernard Ladouche, Giorgia Lucianetti, W. George Darling, Jean-Baptiste Charlier, Tom Gleeson, Heike Brielmann, Maria Filippini, Andreas Hartmann, Yoshihide Wada, Harald Kunstmann, Lhoussaine Bouchaou, Matías Mudarra, Thorsten Wagener, Jakob Garvelmann, Nico Goldscheider, Bartolomé Andreo, Scott Jasechko, University of Freiburg [Freiburg], University of California [Santa Barbara] (UCSB), University of California, University of Victoria [Canada] (UVIC), International Institute for Applied Systems Analysis [Laxenburg] (IIASA), Universidad de Málaga [Málaga] = University of Málaga [Málaga], Environment Agency Austria, Université Ibn Zohr [Agadir], Bureau de Recherches Géologiques et Minières (BRGM) (BRGM), Gestion de l'Eau, Acteurs, Usages (UMR G-EAU), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-AgroParisTech-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), British Geological Survey [Wallingford], British Geological Survey (BGS), Alma Mater Studiorum University of Bologna (UNIBO), Karlsruhe Institute of Technology (KIT), Institute of Nanotechnology [Karlsruhe] (INT), University of Vienna [Vienna], Roma Tre University, University of Patras [Patras], University of the West of England [Bristol] (UWE Bristol), German Research Foundation (DFG) - HA 8113/1-1, Alexander von Humboldt Foundation, Hartmann A., Jasechko S., Gleeson T., Wada Y., Andreo B., Barbera J.A., Brielmann H., Bouchaou L., Charlier J.-B., Darling W.G., Filippini M., Garvelmann J., Goldscheider N., Kralik M., Kunstmann H., Ladouche B., Lange J., Lucianetti G., Martin J.F., Mudarra M., Sanchez D., Stumpp C., Zagana E., and Wagener T.
- Subjects
010504 meteorology & atmospheric sciences ,Population ,0207 environmental engineering ,Glycine ,Aquifer ,02 engineering and technology ,01 natural sciences ,Middle East ,Contamination ,Africa, Northern ,Water Supply ,Groundwater pollution ,Water Movements ,Humans ,Computer Simulation ,020701 environmental engineering ,education ,Groundwater ,Water Movement ,0105 earth and related environmental sciences ,Pollutant ,geography ,education.field_of_study ,Multidisciplinary ,geography.geographical_feature_category ,Models, Statistical ,Groundwater recharge ,Infiltration (HVAC) ,Recharge ,6. Clean water ,Europe ,13. Climate action ,[SDE]Environmental Sciences ,Physical Sciences ,Environmental science ,Carbonate rock ,Water resource management ,Water Pollutants, Chemical ,Human ,Environmental Monitoring - Abstract
International audience; Groundwater pollution threatens human and ecosystem health in many regions around the globe. Fast flow to the groundwater through focused recharge is known to transmit short-lived pollutants into carbonate aquifers, endangering the quality of groundwaters where one quarter of the world’s population lives. However, the large-scale impact of such focused recharge on groundwater quality remains poorly understood. Here, we apply a continental-scale model to quantify the risk of groundwater contamination by degradable pollutants through focused recharge in the carbonate rock regions of Europe, North Africa, and the Middle East. We show that focused recharge is the primary reason for widespread rapid transport of contaminants to the groundwater. Where it occurs, the concentration of pollutants in groundwater recharge that have not yet degraded increases from
- Published
- 2021
34. A worldwide pharmacovigilance database analysis to assess the risk of acute kidney injury in patients receiving teicoplanin in association with piperacillin, cefepime or meropenem
- Author
-
Caroline Charlier, Laurent Chouchana, Solen Kernéis, Jean-Marc Treluyer, and Adrien Contejean
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Cefepime ,MEDLINE ,Meropenem ,Pharmacovigilance ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Piperacillin ,Pharmacology ,Teicoplanin ,business.industry ,Acute kidney injury ,Acute Kidney Injury ,medicine.disease ,Anti-Bacterial Agents ,Infectious Diseases ,business ,medicine.drug - Published
- 2021
35. Assessment of children’s exposure to currently used pesticides in wallonia, Belgium
- Author
-
Léa Champon, Catherine Pirard, Suzanne Remy, Corinne Charlier, and Arnaud Giusti
- Subjects
Male ,0301 basic medicine ,Air Pollutants ,geography ,geography.geographical_feature_category ,Environmental Exposure ,General Medicine ,Pesticide ,Toxicology ,Ambient air ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Belgium ,Biomonitoring ,Spring (hydrology) ,Humans ,Environmental science ,Female ,Pesticides ,Child ,030217 neurology & neurosurgery ,Environmental Monitoring ,Morning - Abstract
In spring 2016, a study was carried out to characterize currently used pesticide (CUP) exposure among children living in Wallonia (Belgium). Pesticides were measured in both first morning urine voids of 258 children aged from 9 to 12 years and in ambient air collected close to the children's schools. Out of the 46 pesticides measured in the air, 19 were detected with frequencies varying between 11 % and 100 %, and mean levels ranging from0.04 to 2.37 ng/m³. Only 3 parent pesticides were found in 1-10% of the urine samples, while all the metabolites analyzed were positively detected at least once. The captan metabolite (THPI) was quantified in 23.5 % of the samples, while 3,5,6-trichloro-2-pyridinol (chlopryrifos metabolite) was detected in all urines with levels ranging from 0.36-38.96 μg/l. 3-phenoxybenzoic acid (3-PBA), trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (t-DCCA) and diethylphosphate were the most abundant pyrethroid metabolites and dialkylphosphate measured. The air inhalation was demonstrated to be a minor route of exposure for the selected CUPs. Statistical regressions highlighted predictors of exposure for some pesticides such like consumption of grey bread, presence of carpets at home or indoor use of pesticides, although no clear source was identified for most of them.
- Published
- 2020
36. Systemic Modelling in Bioethics
- Author
-
Henri-Corto Stoeklé, Christian Hervé, Guillaume Vogt, Philippe Charlier, and Marie-France Mamzer-Bruneel
- Subjects
Systems Analysis ,Organisms, Genetically Modified ,Ethical issues ,Computer science ,business.industry ,Management science ,Genetic Therapy ,Bioethics ,Models, Theoretical ,Issues, ethics and legal aspects ,Humans ,Identification (biology) ,Genetic Testing ,Personalized medicine ,Precision Medicine ,business ,Ethical Analysis - Abstract
We present here a new method for bioethics: systemic modelling. In this method, the complex phenomenon being studied (e.g. personalized medicine, genetic testing, gene therapy, genetically modified organisms) is modelled as a whole, to shed light on its organization and functioning, and major (bio)ethical issues and solutions for their resolution are then identified. This systemic modelling method is ideal for use in the identification of solutions, rather than their validation, with other methods then used to test the solutions found. We provide a description and reproducible instructions for the application of systemic modelling in bioethics, together with a brief example of the application of this method to the study of the impact of personalized medicine on French society.
- Published
- 2020
37. Blood, perceptions, resource and ownership: When transfusion illustrates the complexity
- Author
-
Jean-Daniel Tissot, Olivier Garraud, and Philippe Charlier
- Subjects
medicine.medical_specialty ,Hematology ,Property (philosophy) ,Magic (illusion) ,media_common.quotation_subject ,Ownership ,Biochemistry (medical) ,Clinical Biochemistry ,Academies and Institutes ,Environmental ethics ,Humanism ,Object (philosophy) ,Common good ,Physicians ,Internal medicine ,Irrational number ,Perception ,medicine ,Humans ,Blood Transfusion ,Sociology ,media_common - Abstract
Blood is apart from the rest of the tissues as this fluid is overseen by basic and applied life and humanistic sciences. Blood is the essence of human functioning. It is the object of one of the most commonly known cancers, leukemia. It is life-saving in transfusion – a property that also gives blood a special credit and questions blood as a valuable merchandise or as no ones’ property but common good. But blood is also scandalous after the tainted blood affair in the 1980s and 1990s. Blood is further inseparable from most religious practices, both forefront and hidden (magic cults). It is frightening as it is versed in legitimate and illegitimate combats; it is poured to compensate offenses or debts in many civilizations. Any time blood comes forefront, rationale science leaves it to irrational digressions. Even the very same life-saving transfusion, is beaten by groups of opponents on religious grounds. Further, at a time blood cells and molecules are scrutinized, no one can claim having a complete understanding of what blood is, off the vasculature, as – to study it – one has to alter it. The study of blood is fascinating for all colleges of an academy and not many topics can share this property: chemists, physicists, geneticists, physiologists, medical doctors, philosophers, ethicists, theologians, artists, historicists, anthropologists, sociologists, etc. have all contributed to depict different, specific, aspects of blood. The present review aims at merging different aspects of blood to give pathophysiologists a platform to better understand fears and hopes related to this special tissue, when dealing with patients of theirs.
- Published
- 2020
38. Causes of fever in pregnant women with acute undifferentiated fever: a prospective multicentric study
- Author
-
Camille Levallois, Caroline Charlier, Marc Dommergues, Marc Lecuit, Elie Azria, Thierry Cachina, François Goffinet, Philippe Ravaud, Elodie Perrodeau, Laurent Salomon, DIAKITE, andrée, Biologie des Infections - Biology of Infection, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence Listeria - National Reference Center Listeria (CNRL), Centre collaborateur de l'OMS Listeria / WHO Collaborating Centre Listeria (CC-OMS / WHO-CC), Institut Pasteur [Paris] (IP)-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Service des Maladies infectieuses et tropicales [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Centre hospitalier Saint-Joseph [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), Maternité Port-Royal [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], This study received funding from Programme hospitalier de recherche clinique, Institut Pasteur, Inserm, Santé Publique France., Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris]-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Paris (UP)
- Subjects
Adult ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Pediatrics ,Fever ,[SDV]Life Sciences [q-bio] ,030106 microbiology ,Context (language use) ,Rubella ,Disease Outbreaks ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Pregnancy ,Epidemiology ,medicine ,Humans ,Listeriosis ,Prospective Studies ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,undifferentiated fever ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,Bacterial Infections ,General Medicine ,medicine.disease ,Toxoplasmosis ,3. Good health ,[SDV] Life Sciences [q-bio] ,Pneumonia ,Infectious Diseases ,Virus Diseases ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Etiology ,pyelonephritis ,Female ,France ,Pregnant Women ,influenza ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Cohort study - Abstract
International audience; The etiologies of undifferentiated fever in pregnant women have not been studied thoroughly. Because of its non-specific presentation but severe prognosis, listeriosis is often suspected in this setting, but in most cases not confirmed. We studied the causes of undifferentiated fever in pregnant women who received preemptive listeriosis treatment. We conducted from November 1, 2011, to June 30, 2013, a prospective multicentric observational cohort study of pregnant women referred to obstetrical wards with undifferentiated fever and who received listeriosis preemptive treatment. Clinical and biological features, treatment, outcome, and final diagnosis were collected. We enrolled 103 febrile pregnant women. A cause was identified in 77/103 (75%): viral infection in 52/103 (50%, influenza in 21 (20%)), bacterial infection in 22 (21%, including 16 pyelonephritis (16%) and 3 pneumonias (3%)), and TORCH infection in 3 (3%, varicella, toxoplasmosis, and cytomegalovirus primo-infections, n=1, each). Viral infections collected during influenza outbreaks (December–March) accounted for 43/57 (75%) cases. Two fetal losses were reported in the context of febrile pneumonia. Final diagnoses required adapting medical care in 46/77 (60%) of cases, for bacterial, influenza, or TORCH infections. A large array of benign to potentially severe infections manifests as acute undifferentiated fever in pregnant women, requiring careful repeated evaluation.
- Published
- 2020
39. Insect Cells-Baculovirus System for the Production of Difficult to Express Proteins: From Expression Screening for Soluble Constructs to Protein Quality Control
- Author
-
Simon, Pichard, Nathalie, Troffer-Charlier, Isabelle, Kolb-Cheynel, Pierre, Poussin-Courmontagne, Wassim, Abdulrahman, Catherine, Birck, Vincent, Cura, and Arnaud, Poterszman
- Subjects
Insecta ,Genetic Vectors ,Cell Culture Techniques ,Animals ,Humans ,Baculoviridae ,Recombinant Proteins - Abstract
Rapid preparation of proteins for functional and structural analysis is a major challenge both in academia and industry. The number potential targets continuously increases and many are difficult to express proteins which, when produced in bacteria, result in insoluble and/or misfolded recombinant proteins, protein aggregates, or unusable low protein yield. We focus here on the baculovirus expression vector system which is now commonly used for heterologous production of human targets. This chapter describes simple and cost-effective protocols that enable iterative cycles of construct design, expression screening and optimization of protein production. We detail time- and cost-effective methods for generation of baculoviruses by homologous recombination and titer evaluation. Handling of insect cell cultures and preparation of bacmid for cotransfection are also presented.
- Published
- 2022
40. Lipid nano-vesicles for thyroid hormone encapsulation: A comparison between different fabrication technologies, drug loading, and an in vitro delivery to human tendon stem/progenitor cells in 2D and 3D culture
- Author
-
E.P. Lamparelli, M.C. Ciardulli, P. Scala, M. Scognamiglio, B. Charlier, P. Di Pietro, V. Izzo, C. Vecchione, N. Maffulli, and G. Della Porta
- Subjects
Tendons ,Technology ,Thyroid Hormones ,Stem Cells ,Liposomes ,Phosphatidylcholines ,Pharmaceutical Science ,Humans - Abstract
Phosphatidylcholine (PC) vesicles loaded with Triiodothyronine (T3) were fabricated using different manufacturing methods: thin layer hydration plus sonication (TF-UF), supercritical liposome formation (SC), and microfluidic technology (MF). Vesicles obtained by MF had the lowest mean diameter (88.61 ± 44.48 nm) with a Zeta Potential of -20.1 ± 5.90 mV and loading of 10 mg/g (encapsulation efficiency: 57%). In contrast, SC vesicles showed extremely low encapsulation efficiency (10%) probably due to T3 solubility in ethanol/carbon dioxide mixture; despite TF-UF vesicles exhibiting good size (167.7 ± 90 nm; Zp -8.50 ± 0.60 mV) and loading (10 mg/g), poor mass recovery was obtained (50% loss). MF vesicles had low cytotoxicity, and they were well enough internalized by both HeLa and human tendon stem/progenitor cells (hTSPCs). Their biological activity was also monitored in both 2D and 3D cultures of hTSPCs supplemented with therapeutical concentrations of PC/T3 nano-liposomes. 2D culture showed almost similar constitutive gene expression compared to control culture supplemented with free-T3. On the contrary, when hTPSCs 3D culture was assembled, it showed a more evident homogeneous distribution of FITC labeled vesicles within the high-density structure and a significant upregulation of cell constitutive genes, such as type I Collagen (4.8-fold; p 0.0001) at day 7, compared to the control, suggesting that T3/PC formulation has increased T3 cytosolic concentration, thus improving cells metabolic activity. The study supported MF technology for nano-carriers fabrication and opens perspectives on the activity of PC/T3 nano-vesicles as innovative formulations for TPSCs stimulation in ECM secretion.
- Published
- 2022
41. The Internal Cranial Anatomy of a Female With Endocrine Disorders From a Mediaeval Population
- Author
-
Kubicka, Anna Maria, Charlier, Philippe, and Balzeau, Antoine
- Subjects
Adult ,Endocrinology, Diabetes and Metabolism ,Acromegaly ,Skull ,Humans ,Female ,Endocrine System Diseases ,Head ,Gigantism - Abstract
Gigantism and acromegaly have been observed in past populations; however, analyses usually focus on the morphological features of the post-cranial skeleton. The aim of this study is to characterize the internal anatomical features of the skull (brain endocast anatomy and asymmetry, frontal pneumatization, cranial thickness, sella turcica size) of an adult individual from the 11-14th centuries with these two diseases, in comparison with non-pathological individuals from the same population. The material consisted of 33 adult skulls from a mediaeval population, one of them belonging to an adult female with endocrine disorders (OL-23/77). Based on the CT scans, the internal cranial anatomy was analysed. The sella turcica of OL-23/77 is much larger than in the comparative sample. The endocast of the individual OL-23/77 shows a left frontal/left occipital petalia, while the comparative population mostly had right frontal/left occipital petalias. The asymmetry in petalia location in OL-23/77 comes within the range of variation observed in the comparative population. The individual has high values for cranial thickness. The frontal sinuses of the specimen analysed are similar in size and shape to the comparative sample only for data scaled to the skull length. Enlarged sella turcica is typical for individuals with acromegaly/gigantism. The pattern of the left frontal/left occipital petalia in the specimen OL-23/77 is quite rare. The position of the endocranial petalias has not influenced the degree of asymmetry in the specimen. Despite the large bone thickness values, skull of OL-23/77 does not show any abnormal features. The skull/endocast relationship in this individual shows some peculiarities in relation to its large size, while other internal anatomical features are within the normal range of variation of the comparative sample.
- Published
- 2022
42. Antibiotic prophylaxis in preterm premature rupture of membranes at 24–31 weeks’ gestation: Perinatal and 2‐year outcomes in the EPIPAGE‐2 cohort
- Author
-
Lorthe, Elsa, Letouzey, Mathilde, Torchin, Héloïse, Foix L'Helias, Laurence, Gras‐le Guen, Christèle, Benhammou, Valérie, Boileau, Pascal, Charlier, Caroline, Kayem, Gilles, Ancel, Pierre‐yves, Arnaud, Catherine, Blanc, Julie, Debillon, Thierry, Delorme, Pierre, D’ercole, Claude, Desplanches, Thomas, Diguisto, Caroline, Gascoin, Géraldine, Gire, Catherine, Goffinet, François, Langer, Bruno, Maisonneuve, Emeline, Marret, Stéphane, Monier, Isabelle, Morgan, Andrei, Rozé, Jean‐christophe, Schmitz, Thomas, Sentilhes, Loïc, Subtil, Damien, Tosello, Barthélémy, Vayssière, Christophe, Winer, Norbert, Zeitlin, Jennifer, Astruc, D, Kuhn, P, Matis, J, Ramousset, C, Hernandorena, X, Chabanier, P, Joly‐pedespan, L, Costedoat, Mj, Leguen, A, Lecomte, B, Lemery, D, Vendittelli, F, Beucher, G, Dreyfus, M, Guillois, B, Toure, Y, Burguet, A, Couvreur, S, Gouyon, Jb, Sagot, P, Colas, N, Sizun, J, Beuchée, A, Pladys, P, Rouget, F, Dupuy, Rp, Soupre, D, Charlot, F, Roudaut, S, Favreau, A, Saliba, E, Reboul, L, Bednarek, N, Morville, P, Verrière, V, Thiriez, G, Balamou, C, Marpeau, L, Barbier, C, Durrmeyer, X, Granier, M, Ayoubi, M, Baud, O, Carbonne, B, Jarreau, Ph, Mitanchez, D, Duffaut, C, Cornu, L, Moras, R, Boulot, P, Cambonie, G, Daudé, H, Badessi, A, Tsaoussis, N, Bédu, A, Mons, F, Bahans, C, Binet, Mh, Fresson, J, Hascoët, Jm, Milton, A, Morel, O, Vieux, R, Hilpert, L, Alberge, C, Baron, M, Charkaluk, Ml, Pierrat, V, Truffert, P, Akowanou, S, Simeoni, U, Bongain, A, Deschamps, M, Branger, B, Rouger, V, Dupont, C, Gondry, Jean, Krim, G, Baby, B, Debeir, M, Claris, O, Picaud, Jc, Rubio‐gurung, S, Cans, C, Ego, A, Patural, H, Rannaud, A, Janky, E, Poulichet, A, Rosenthal, Jm, Coliné, E, Favre, A, Joly, N, Châlons, S, Pignol, J, Laurence, Pl, Robillard, Py, Samperiz, S, Ramful, D, Blondel, B, Bonet, M, Brinis, A, Coquelin, A, Durox, M, Kaminski, M, Khemache, K, Khoshnood, B, Lebeaux, C, Marchand‐martin, L, Rousseau, J, Saurel‐cubizolles, Mj, Tran, D, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris], Assistance Publique - Hôpitaux de Paris, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service Epidémiologie clinique et santé publique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Unité de biostatistiques [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Médecine Néonatale et Réanimation Pédiatrique CHU Grenoble, CHU Grenoble, Service de gynécologie-obstétrique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Service de Gynécologie Obstétrique, Médecine Foetale et Stérilité Conjugale - Chirurgie Gynécologie et Oncologique [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Néonatologie, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Recherches épidémiologiques en santé périnatale et santé des femmes, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Groupe de Recherche sur l'Analyse Multimodale de la Fonction Cérébrale - UMR INSERM_S 1105 (GRAMFC), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Amiens-Picardie, Funding information:This work was partly supported by a postdoctoral grant from the Fondation des Treilles to EL. EPIPAGE-2 was funded by the French Institute of Public Health Research (IRESP TGIR 2009-01 programme)/Institute of Public Health and its partners: the French Health Ministry, the National Institute of Health and Medical Research (INSERM), the National Institute of Cancer, and the National Solidarity Fund for Autonomy (CNSA), the National Research Agency through the French EQUIPEX programme of investments for the future (grant number ANR-11-EQPX-0038), and the PREMUP Foundation. Additional funding was obtained from Fondation pour la Recherche Medicale (grant number SPF 20160936356) and Fondation de France (grant numbers 00050329, Grand Prix R18202KK]). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., ANR-11-EQPX-0038,RE-CO-NAI,Plateforme de REcherche sur les COhortes d'enfants suivis depuis la NAIssance(2011), Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Education, Formation, Travail, Savoirs (EFTS), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-École Nationale Supérieure de Formation de l'Enseignement Agricole de Toulouse-Auzeville (ENSFEA), École Nationale Supérieure de Formation de l'Enseignement Agricole de Toulouse-Auzeville (ENSFEA), Centre Hospitalier Universitaire [Grenoble] (CHU), Modélisation et Évaluation des données complexes en Santé Publique (TIMC-MESP), Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), CHU Dijon, Hôpital Nord [CHU - APHM], Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Department of Obstetrics and Gynecology, Les Hôpitaux Universitaires de Strasbourg (HUS), EPIPAGE-2 Study Group, and Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Fetal Membranes, Premature Rupture ,obstetric intervention ,[SDV]Life Sciences [q-bio] ,Gestational Age ,antenatal management ,Cohort Studies ,Pregnancy ,Escherichia coli ,Humans ,Prospective Studies ,latency ,amoxicillin ,neurodevelopment ,macrolides ,prematurity ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,Infant ,prophylactic antibiotics ,Antibiotic Prophylaxis ,Anti-Bacterial Agents ,perinatal outcome ,cephalosporins ,Premature Birth ,Female ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Neonatal Sepsis ,Infant, Premature - Abstract
To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age.Prospective, nationwide, population-based EPIPAGE-2 cohort study of preterm infants.France, 2011.We included 492 women with a singleton pregnancy and a diagnosis of preterm premature rupture of membranes at 24-31 weeks. Exclusion criteria were contraindication to expectant management or indication for antibiotic therapy other than preterm premature rupture of membranes. Antibiotic prophylaxis was categorised as amoxicillin (n = 345), macrolide (n = 30), third-generation cephalosporin (n = 45) or any combinations covering Streptococcus agalactiae and90% of Escherichia coli (n = 72), initiated within 24 hours after preterm premature rupture of membranes.Population-averaged robust Poisson models.Survival at discharge without severe neonatal morbidity, 2-year neurodevelopment.With amoxicillin, macrolide, third-generation cephalosporin and combinations, 78.5%, 83.9%, 93.6% and 86.0% of neonates were discharged alive without severe morbidity. The administration of third-generation cephalosporin or any E. coli-targeting combinations was associated with improved survival without severe morbidity (adjusted risk ratio 1.25 [95% confidence interval 1.08-1.45] and 1.10 [95 % confidence interval 1.01-1.20], respectively) compared with amoxicillin. We evidenced no increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen.In preterm premature rupture of membranes at 24-31 weeks, antibiotic prophylaxis based on third-generation cephalosporin may be associated with improved survival without severe neonatal morbidity when compared with amoxicillin, with no evidence of increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogen.Antibiotic prophylaxis after PPROM at 24-31 weeks: 3rd-generation cephalosporins associated with improved neonatal outcomes.
- Published
- 2022
43. Association between glycemic control and risk of venous thromboembolism in diabetic patients: a nested case–control study
- Author
-
Susan S. Jick, Sarah Charlier, Claudia Becker, Christian Meier, and Christoph R. Meier
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,HbA1c ,Time Factors ,endocrine system diseases ,Case–control study ,Endocrinology, Diabetes and Metabolism ,Glycemic Control ,Risk Assessment ,Diabetes mellitus type 2 ,Sex Factors ,Risk Factors ,Internal medicine ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,cardiovascular diseases ,Glycemic ,Original Investigation ,Aged ,Aged, 80 and over ,Glycated Hemoglobin ,business.industry ,Incidence ,nutritional and metabolic diseases ,Venous Thromboembolism ,Middle Aged ,equipment and supplies ,United Kingdom ,Treatment Outcome ,Diabetes Mellitus, Type 2 ,RC666-701 ,Case-Control Studies ,Nested case-control study ,Sex ,Female ,VTE ,Cardiology and Cardiovascular Medicine ,business ,Venous thromboembolism ,Biomarkers - Abstract
Background Previous studies suggested an elevated risk of venous thromboembolism (VTE) among patients with type 2 diabetes mellitus (T2DM), with a possible sex difference. The impact of glycemic control on the risk of VTE is unclear. Our objective was to analyze the association between glycemic control and the risk of unprovoked (idiopathic) VTE in men and women with T2DM. Methods We conducted a nested case–control analysis (1:4 matching) within a cohort of patients with incident T2DM between 1995 and 2019 using data from the CPRD GOLD. We excluded patients with known risk factors for VTE prior to onset of DM. Cases were T2DM patients with an unprovoked treated VTE. The exposure of interest was glycemic control measured as HbA1c levels. We conducted conditional logistic regression analyses adjusted for several confounders. Results We identified 2′653 VTE cases and 10′612 controls (53.1% females). We found no association between the HbA1c level and the risk of VTE in our analyses. However, when the most recent HbA1c value was recorded within 90 days before the index date, women with HbA1c levels > 7.0% had a 36–55% increased relative risk of VTE when compared to women with HbA1c > 6.5–7.0%. Conclusions Our study raises the possibility that female T2DM patients with HbA1c levels > 7% may have a slightly higher risk for unprovoked VTE compared to women with HbA1c levels > 6.5–7.0%. This increase may not be causal and may reflect differences in life style or other characteristics. We observed no effect of glycemic control on the risk of VTE in men.
- Published
- 2022
44. Developing evaluation capacities in integrated care projects : lessons from a scientific support mission implemented in Belgium
- Author
-
Nathan Charlier, Elien Colman, Lucia Alvarez Irusta, Sibyl Anthierens, Thérèse Van Durme, Jean Macq, Benoit Pétré, and UCL - SSS/IRSS - Institut de recherche santé et société
- Subjects
Patient Care Team ,Population Health ,Delivery of Health Care, Integrated ,Health Personnel ,Public Health, Environmental and Occupational Health ,evaluation capacity building ,apply research ,learning community ,scientific support ,decision making ,evaluation capacity ,information-based approach ,Belgium ,integrated care programs ,Humans ,Public Health ,Human medicine - Abstract
The capacity of self-assessment, to learn from experience, to make information-based decisions, and to adapt over time are essential drivers of success for any project aiming at healthcare system change. Yet, many of those projects are managed by healthcare providers' teams with little evaluation capacity. In this article, we describe the support mission delivered by an interdisciplinary scientific team to 12 integrated care pilot projects in Belgium, mobilizing a set of tools and methods: a dashboard gathering population health indicators, a significant event reporting method, an annual report, and the development of a sustainable “learning community.” The article provides a reflexive return on the design and implementation of such interventions aimed at building organizational evaluation capacity. Some lessons were drawn from our experience, in comparison with the broader evaluation literature: The provided support should be adapted to the various needs and contexts of the beneficiary organizations, and it has to foster experience-based learning and requires all stakeholders to adopt a learning posture. A long-time, secure perspective should be provided for organizations, and the availability of data and other resources is an essential precondition for successful work.
- Published
- 2022
45. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
- Author
-
Jonathan P Piccini, Valeria Caso, Stuart J Connolly, Keith A A Fox, Jonas Oldgren, W Schuyler Jones, Diana A Gorog, Václav Durdil, Thomas Viethen, Christoph Neumann, Hardi Mundl, Manesh R Patel, Johann Auer, Martin Hubauer, Sead Pandzic, Eva Preishuber, Carina Primus-Grabscheit, Dietmar Reitgruber, Florian Schmalzer, Christopher Adlbrecht, Andreas Schober, Johannes Hajos, Christoph Keil, Alexandra Schratter, Matthias Frick, Magdalena Anna Benda, Maximilian Mächler, Beatrix Mutschlechner, Christoph Saely, Lukas Sprenger, Michael Lichtenauer, Miriam Eber, Uta Hoppe, Tobias Kolbitsch, Peter Michael Jirak, Moritz Mirna, Robert Schönbauer, Jutta Bergler-Klein, Christian Hengstenberg, Stefan Stojkovic, Daniel Scherr, Martin Manninger-Wünscher, Ursula Rohrer, Markus Stühlinger, Wilfried Schgoer, Jana Schwarzl, Helmut Pürerfellner, Michael Derndorfer, Christian Ebner, Veronika Eder, Georgios Kollias, Thomas Sturmberger, Stefan Sieghartsleitner, Johan Vijgen, Peter Koopman, Karl Dujardin, Wim Anné, Michel De Ceuninck, Rene Tavernier, Mattias Duytschaever, Sébastien Knecht, Luc Missault, Yves Vandekerckhove, Tom Rossenbacker, Bavo Ector, Filip Charlier, Philippe Debruyne, Willem Dewilde, Luc Janssens, John Roosen, Bart Vankelecom, Hein Heidbuchel, Michiel Delesie, Gert Vervoort, Hans Rombouts, Thomas Vanassche, Matthias Engelen, Peter Verhamme, Rik Willems, Christian Constance, Nicolas Pranno, Jafna Cox, Iqbal Bata, Laurent Macle, Martin Aguilar, Julia Cadrin Tourigny, Marc Dubuc, Katia Dyrda, Peter Guerra, Paul Khairy, Blandine Mondésert, Léna Rivard, Denis Roy, Rafik Tadros, Mario Talajic, Bernard Thibault, Isabelle Nault, Louis Blier, Jean Champagne, Franck Molin, Gilles O'Hara, François Philippon, Benoit Plourde, Jean-François Sarrazin, Christian Steinberg, Zdenek Coufal, David Balazsik, Michal Mikulica, Jakub Zapeca, Ondrej Cermak, Tomas Drasnar, Matej Falc, Josef Hornof, Blazej Racz, Danica Weissova, Hana Linkova, Eva Paskova, Robert Petr, Andrea Sirakova, Jiri Kettner, Ales Benak, Martin Holek, Ivo Podpera, Monika Podperova, Vlastimil Vancura, Tomas Jandik, Jiri Smid, Vratislav Dedek, Jan Banik, Vaclav Durdil, Tomas Hnat, Nicolas Lellouche, Ségolène Rouffiac, Guillaume Taldir, Valentin Bridonneau, Philippe Couffon, Magalie Daudin, Cécile Hamon, Jonathan Lacaze, Anne Quentin, Christophe Thebault, Emmanuel Boiffard, Olivier Billon, Fabien Miette, Hervé Pouliquen, Guillaume Turlotte, Hervé Gorka, Franck Albert, Sandrine Bayle, Reda Bensaid, Madalina Dasoveanu, Thibaud Demichili, Teodora Dutoiu, Cliff Khalil, Caterina Loghin, Grégoire Range, Laurent Roussel, Pierre Socié, Christophe Thuaire, Fabrice Extramiana, Vincent Algalarrondo, Haten Boughanmi, Noreddine El Mansour, Usman Mohammad, Romain Sellier, Meyer Elbaz, Clémence Laperche, Philippe Maury, Robert Kiss, Tunde Borsanyi, Zoltan Gingl, Balaza Polgar, Bela Benczur, Alexandra Bodor, Tamas Hepp, Eva Malati, Laszlo Nagy, Norbert Erdei, Jozsef Kapus, Katalin Kapus, Brigitta Toth, Andras Matoltsy, Tunde Kiss, Bela Merkely, Szilvia Herczeg, Orsolya Kiss, Zoltan Sallo, Kalman Toth, Tamas Habon, Miklos Rabai, Kinga Totsimon, Zsolt Zilahi, Gabriella Bencze, Janos Santa, Daniel Aradi, Barbara Kelemen, Leonardo Bolognese, Martina Nesti, Pasquale Giovanni Notarstefano, Simona D'Orazio, Franco Cosmi, Cecilia Becattini, Giancarlo Agnelli, Belinda Broccatelli, Maria Giulia Mosconi, Maurizio Paciaroni, Chiara Urbini, Vito Maurizio Parato, Camilla Notaristefani, Michele Scarano, Pietro Ameri, Giorgio Ghigliotti, Giulia Guglielmi, Roberta Lotti, Andrea Carlo Merlo, Maria Lorenza Muiesan, Andrea Abondio, Caterina Berasi, Elena Mattiuzzo, Claudio Mutti, Massimo Salvetti, Pasquale Pignatelli, Danilo Menichelli, Daniele Pastori, Eiji Tamiya, Takahiro Matsumoto, Tomosato Takabe, Shoichi Yamamoto, Haruyo Yamashita, Shinichi Higashiue, Onichi Furuya, Norihiko Hiramatsu, Kensuke Kasuga, Saburo Kojima, Masatoshi Komooka, Satoshi Kuroyanagi, Makoto Matsuura, Tetsushi Takemoto, Shuji Yamamoto, Katusmi Saito, Takuro Abe, Issei Ishida, Yuji Iwanami, Shohei Kataoka, Tetsu Moriyama, Akira Murohashi, Akihito Sasaki, Yuichiro Nakamura, Tetsuya Ueno, Akira Shimane, Tomoyo Hamana, Hirotoshi Ichibori, Tomohiro Inoue, Mitsuaki Itoh, Seigo Iwane, Hiroya Kawai, Tatsuya Kokawa, Akiko Masumoto, Koki Matsuo, Taishi Miyata, Shinsuke Nakano, Shogo Oishi, Tetsuari Onishi, Takahiro Sawada, Takayuki Saito, Mitsuhiko Shoda, Nobuyuki Takahashi, Tomofumi Takaya, Yasuyo Taniguchi, Shota Tsukamoto, Yasue Tsukishiro, Yoshiro Tsukiyama, Hiroshi Tsunamoto, Kenzo Uzu, Hiroyuki Yamamoto, Tetsuya Yamamoto, Kiminobu Yokoi, Chiaki Yoshida, Nobuhiro Watanabe, Tetsuo Betsuyaku, Kumiko Adachi, Kouichi Awane, Daisuke Goto, Mamoru Sakakibara, Masashi Watanabe, Hideki Ueno, Yoshitaka Hiroe, Koshi Matsuo, Kenji Ayata, Ko Fukuda, Yoshiki Hata, Katsushi Hashimoto, Hiroaki Matsumi, Akira Nikaido, Shuichi Okamoto, Iveta Sime, Valters Stirna, Ilze Reinholde, Silvija Hansone, Anita Kozlovska, Janina Romanova, Dace Klincare, Natalja Pontaga, Igors Dirmans, Artis Kalnins, Dana Upite, Arcils Gersamija, Arturs Teleznikovs, Nadezda Rozkova, Jelena Safro, Ignasi Anguera Camós, Paolo Domenico Dallaglio, Rafael Salguero Bodes, Fernando Arnbas, Luis Borrego, Alvaro Marco, Javier Ramos Jimenez, Juan José Gómez-Doblas, Alejandro Pérez Cabeza, Ignacio Ferreira Gonzålez, Javier Limeres Freire, Merce Lopez Grau, Xavier Viñolas Prat, Zoraida Moreno Weidmann, Jose Maria Guerra Ramos, Maria Concepcion Alonso Martin, Bieito Campos Garcia, Javier Mauricio Mogro Carranza, Francisco Javier Mendez Zurita, Enrique Rodriguez Font, Carlos Eduardo Gonzales Matos, Víctor García Hernando, Carl-Johan Lindholm, Jörgen Thulin, Håkan Wallén, Kristina Hagwall, Ken Eliasson, Martin Lundvall, Jens Olsson, Björn Kjellman, Markus Lind, Lars Johansson, Niclas Svedberg, Stefan Berglund, Julia Söderberg, Christer Zedigh, Thomas Mooe, Mattias Axelsson, Emil Binsell, Daniel Huber, Christian Müller, Isabelle Danier, Michael Kühne, Bernhard Okamura, Hadrien Schoepfer, Cornelia Simmen, Tobias Reichlin, Laurève Chollet, Anna Lam, Severin Wittmer, Hans Rickli, Christian Gall, Greta Hametner, Stephanie Intorp, Daniel Luescher, Laurent Haegeli, Jan Christopher Berg, Ramin Ebrahimi, Angelo Auricchio, Carmela Crljenica, Tizziano Moccetti, Cristina Monti, Elena Pasotti, Iveta Petrova, Mariagrazia Rossi, François Mach, Mehdi Namdar, Joris de Groot, Virginnio Proost, Joline Neefs, Dominik Linz, Twan van Stipdonk, Dennis den Uijl, Marco Alings, Jeroen Schaap, Dolf Segers, Noemi Wouters, Louis Bartels, Robert Tieleman, Ron Pisters, Tim de Vries, Jaap Selig, Aaf Kuijper, Pieter Bot, Mitran Keijzers, Gerardus Verdel, Raymond Tukkie, Ewout van den Bos, Floris Kauer, Rohit Oemrawsingh, Jeroen Stevenhagen, Jan van Es, Gregory Lip, Dhiraj Gupta, Agnieszka Kotalczyk, Anthony Gunstone, Richard David Brixey, Diana Gorog, Danial Dinarvand, Ying Gue, Rahim Kanji, Vassilios Memtsas, Roxy Senior, Gabriel Bioh, Yuk-Ki Wong, Nick Child, Cardiology, and ACS - Heart failure & arrhythmias
- Subjects
anticoagulants ,factor xa inhibitors ,General Medicine ,aged ,double-blind method ,female ,hemorrhage ,humans ,male ,pyrazoles ,pyridones ,treatment outcome ,atrial fibrillation ,610 Medicine & health - Abstract
BACKGROUND Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might reduce thrombosis with minimal effect on haemostasis. We aimed to determine the optimal dose of asundexian and to compare the incidence of bleeding with that of apixaban in patients with atrial fibrillation. METHODS In this randomised, double-blind, phase 2 dose-finding study, we compared asundexian 20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older with atrial fibrillation, a CHA2DS2-VASc score of at least 2 if male or at least 3 if female, and increased bleeding risk. The study was conducted at 93 sites in 14 countries, including 12 European countries, Canada, and Japan. Participants were randomly assigned (1:1:1) to a treatment group using an interactive web response system, with randomisation stratified by whether patients were receiving a direct-acting oral anticoagulant before the study start. Masking was achieved using a double-dummy design, with participants receiving both the assigned treatment and a placebo that resembled the non-assigned treatment. The primary endpoint was the composite of major or clinically relevant non-major bleeding according to International Society on Thrombosis and Haemostasis criteria, assessed in all patients who took at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT04218266, and EudraCT, 2019-002365-35. FINDINGS Between Jan 30, 2020, and June 21, 2021, 862 patients were enrolled. 755 patients were randomly assigned to treatment. Two patients (assigned to asundexian 20 mg) never took any study medication, resulting in 753 patients being included in the analysis (249 received asundexian 20 mg, 254 received asundexian 50 g, and 250 received apixaban). The mean age of participants was 73·7 years (SD 8·3), 309 (41%) were women, 216 (29%) had chronic kidney disease, and mean CHA2DS2-VASc score was 3·9 (1·3). Asundexian 20 mg resulted in 81% inhibition of FXIa activity at trough concentrations and 90% inhibition at peak concentrations; asundexian 50 mg resulted in 92% inhibition at trough concentrations and 94% inhibition at peak concentrations. Ratios of incidence proportions for the primary endpoint were 0·50 (90% CI 0·14-1·68) for asundexian 20 mg (three events), 0·16 (0·01-0·99) for asundexian 50 mg (one event), and 0·33 (0·09-0·97) for pooled asundexian (four events) versus apixaban (six events). The rate of any adverse event occurring was similar in the three treatment groups: 118 (47%) with asundexian 20 mg, 120 (47%) with asundexian 50 mg, and 122 (49%) with apixaban. INTERPRETATION The FXIa inhibitor asundexian at doses of 20 mg and 50 mg once daily resulted in lower rates of bleeding compared with standard dosing of apixaban, with near-complete in-vivo FXIa inhibition, in patients with atrial fibrillation. FUNDING Bayer.
- Published
- 2022
46. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
- Author
-
Caroline Lions, N Biezunski, Sophie Matheron, Romain Guery, Pierre-Marie Roger, Caroline Charlier, Mathieu Dupont, Line Meddeb, Philippe Van de Perre, V Joly, R Lecomte, Matthieu Revest, Claudine Duvivier, B Lefèvre, M Delestan, H Laurichesse, H Marty, F Lemaitre, Martine Valette, Marc-Antoine Valantin, A S Ritleng, A Ménard, Eric Cua, M. Alvarez, A Raoux, M P Bouillon, A Sève, A Brebion, Claire Triffault-Fillit, Sylvie Bregigeon, M Carles, O. Aubry, S Hénard, P. Dellamonica, A Charmillon, E Alidjinou, V Brodard, M Tetart, F Raffi, Paul-Henri Consigny, O Lesens, C Brunet-Cartier, I Lamaury, S Giaché, Amandine Gagneux-Brunon, Jacques Reynes, Karine Sauné, Clotilde Allavena, Q Lepiller, Véronique Reliquet, C Louisin, I Perbost, Jean-Luc Berger, B Prouvost-Keller, Eric Delaporte, Isabelle Lamaury, C Gubavu, L Fagour, Laurent Cotte, G Gaube, Elina Teicher, Faouzi Souala, C Blanc, Dominique Merrien, Isabelle Poizot-Martin, C Drobacheff-Thiébaut, T May, P Richard, M A Trabaud, M Bistoquet, C Klotz, Samira Fafi-Kremer, M Marcel, Charlotte Charpentier, L Lelièvre, K Risso, Sandrine Pierre-François, S Ferrando, S Breaud, S Bevilacqua, A Montoya Ferrer, T Rojas-Rojas, D Boucher, Yazdan Yazdanpanah, Olivier Lortholary, Philippe Colson, Anne-Sophie Brunel, F-Xavier Lescure, Christelle Tomei, M Martin-Degioanni, Eric Rosenthal, Philippe Bossi, Patrick Miailhes, Kevin Bouiller, Lise Cuzin, A Foltzer, F Boulard, Michel Vidal, V Mondain, H Colson, J Pasquier, I Kmiec, F Alby-Laurent, R Agher, A Cabié, Guillaume Martin-Blondel, L Hocqueloux, M Colin, A Madrid, Faiza Ajana, J M Livrozet, V Rio, Karima Amazzough, C Merle de Boever, M Digumber, Thomas Perpoint, A Cheret, Laurence Bocket, Z Julia, Virginie Ferré, M Pradier, M Poisson-Vannier, A Legoff, M J Soavi, Y Quertainmont, Marine Morrier, Christian Chidiac, F Touam, O Zaegel-Faucher, A Marquise, G Benabdelmoumen, Florence Ader, T Guimard, M C Receveur, J C Tardy, P Morineau, K Guitteaud, D. Rey, S Leautez, Catherine Chirouze, Benoit Tressières, A. Ivanova, C Charre, J Reynes, Christian Pradier, Catherine Dhiver, Laurent Boyer, E Frentiu, David Rey, C Allavena, Anne Motte, Tristan Ferry, C Pronier, M. Hentzien, C Rouzaud, O Cabras, K Jidar, F Najioullah, C Clavel, M Orticoni, S Patrat-Delon, M Cavellec, Cécile Herrmann-Storck, V Baclet, Jade Ghosn, M Perry, S Wehrlen-Pugliese, J. M. Chapplain, R Palich, Laurent Hocqueloux, A Maillard, C Deschanvres, O Deradji, F. Lucht, A Grégoire, Veronique Joly, R Ouissa, C Daniel, N Mrozek, D Chirio, O Bollangier, J Bavay, P. Le Turnier, A Maka, C Rioux, Colin Deschanvres, C Brochier, Elisabeth Botelho-Nevers, A Meybeck, C Ceppi, J Lourenco, François Bénézit, Thomas Jovelin, G Zouzou, N Tissot, N. Viget, F Brunel-Dalmas, Brigitte Montes, N Chellum Rungen, K Rome, David Boutoille, B Bigeard, I Fabre, N Oran, M Lefebvre, P Point, C Etienne, Diane Descamps, G Thomas, S Le Gac, Cyrille Delpierre, Pierre Tattevin, M Godinot, P Fischer, C Aumeran, C Boulard, Elisabeth André-Garnier, J Sinteff, V Ronat, F Goehringer, Romain Palich, Luminita Schneider, I Touitou, Eric Billaud, P Thill, Catherine Varache, Olivier Robineau, I Jaquet, Roland Landman, Cédric Arvieux, B. Bonnet, V Rzepecki, Olivier Grossi, Christian Rabaud, L Laine, F Louni, C Cheneau, S Markowicz, Hélène Laroche, A Gervais, C Bernard-Henry, E Goncalvez, N Lerolle, M André, D Lambert, André Boibieux, L. Porte, S Bouchez, E Paredes, E Aïssi, V. Le Moing, S Degroodt, Sylvie Abel, André Cabié, B Lafon-Desmurs, O Babre, M Baldeyrou, C Debreux, A Rodallec, Pierre Delobel, V Icard, Agathe Becker, Edouard Tuaillon, Hervé Tissot-Dupont, M Mokhtari, C Morlat, I Alcaraz, Anne Frésard, O Cannesson, Elodie Curlier, P Chiarello, S. Roux, F Bani-Sadr, François Raffi, Florent Valour, M Piffaut, M Priester, A. Belkhir, J Romaru, Cécile Goujard, A Castro, G Cessot, A Mirand, C Pouderoux, A Brunet, C Michelangeli, Y N’guyen, Patrice Muret, Elisa Demonchy, Christine Jacomet, D Makhloufi, E Jeanmaire, Marialuisa Partisani, Véronique Obry-Roguet, J Turmel, C Mélounou, J. Durant, Christine Katlama, P Parize, O Robineau, S Seang, F. Bozon, S Galie, Alexa Debard, E de Mautort, C Duvivier, Fanny Lanternier, Alain Makinson, A Barrail-Tran, C Aguilar, A Naqvi, Rodolphe Garraffo, N Meftah, C Biron, A de Monte, Pascal Pugliese, V Corbin, S Jaureguiberry, E Lafont, L Hustache Mathieu, R Colarino, Isabelle Ravaux, C Henquell, Benoit Pilmis, M Grégoire, P Lansalot, E Ressiot, T. Huleux, Olivier Baud, S Sécher, R Dupin de Majoubert, J Leporrier, L Cuzin, E Chevalier, M Poinot, R Tubiana, S Lariven, A Boucher, N Atoui, Firouzé Bani-Sadr, T Prazuck, M Ducassou, Gilles Peytavin, A Soria, B J Gaborit, Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Dat’AIDS Study Group, Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Pointe-à-Pitre/Abymes [Guadeloupe], Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Gustave Dron [Tourcoing], Institut Pasteur [Paris] (IP), Centre Hospitalier Régional d'Orléans (CHRO), Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU de la Martinique [Fort de France], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], CHU Clermont-Ferrand, and Université Clermont Auvergne (UCA)
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Anti-HIV Agents ,Pyridones ,MESH: Piperazines ,HIV Infections ,Emtricitabine ,Piperazines ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,MESH: Pyridones ,Oxazines ,MESH: Emtricitabine ,Humans ,Medicine ,Pharmacology (medical) ,MESH: Anti-HIV Agents ,Pharmacology ,MESH: Heterocyclic Compounds, 3-Ring ,MESH: Humans ,business.industry ,Rilpivirine ,Lamivudine ,MESH: HIV Infections ,Viral Load ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,Virological failure ,Regimen ,Infectious Diseases ,chemistry ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Dolutegravir ,Cohort ,MESH: Rilpivirine ,business ,MESH: Viral Load ,Heterocyclic Compounds, 3-Ring ,MESH: Oxazines ,medicine.drug ,MESH: Lamivudine - Abstract
Background Maintenance ART with dolutegravir-based dual regimens have proved their efficacy among HIV-1-infected subjects in randomized trials. However, real-life data are scarce, with limited populations and follow-up. Objectives We assessed virological failure (VF) and resistance-associated mutations (RAMs) on dolutegravir maintenance regimens in combination with rilpivirine or with lamivudine or emtricitabine (xTC) and analysed the factors associated with VF. Methods Between 2014 and 2018, all HIV-1-infected adults included in the Dat’AIDS cohort and starting dolutegravir/rilpivirine or dolutegravir/xTC as a maintenance dolutegravir-based dual regimen were selected. VF was defined as two consecutive HIV RNA values >50 copies/mL or a single value >400 copies/mL. We compared cumulative genotypes before initiation of a maintenance dolutegravir-based dual regimen with genotype at VF. Results We analysed 1374 subjects (799 on dolutegravir/rilpivirine and 575 on dolutegravir/xTC) with a median follow-up of 20 months (IQR = 11–31) and 19 months (IQR = 11–31), respectively. VF occurred in 3.8% (n = 30) of dolutegravir/rilpivirine subjects and 2.6% (n = 15) of dolutegravir/xTC subjects. Among subjects receiving dolutegravir/rilpivirine, two genotypes harboured emerging RAMs at VF: E138K on NNRTI (n = 1); and E138K+K101E on NNRTI and N155H on INSTI (n = 1). Among subjects receiving dolutegravir/xTC, no new RAM was detected. The only predictive factor of VF on dolutegravir/rilpivirine was the history of failure on an NNRTI-based regimen (adjusted HR = 2.97, 95% CI = 1.28–6.93). No factor was associated with VF on dolutegravir/xTC. Conclusions In this large real-life cohort, dolutegravir/rilpivirine and dolutegravir/xTC sustained virological suppression and were associated with a low rate of VF and RAM emergence. Careful virological screening is essential before switching to dolutegravir/rilpivirine in virologically suppressed patients with a history of NNRTI therapy.
- Published
- 2022
47. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)
- Author
-
Laure‐Hélène Préta, Adrien Contejean, Francesco Salvo, Jean‐Marc Treluyer, Caroline Charlier, Laurent Chouchana, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and CHU Bordeaux [Bordeaux]
- Subjects
Pharmacology ,Adult ,Aged, 80 and over ,Herpesvirus 3, Human ,Disproportionality ,COVID-19 Vaccines ,Vaccination ,COVID-19 ,Herpes Zoster ,mRNA vaccines ,Pharmacovigilance ,Influenza Vaccines ,Herpes Zoster Vaccine ,Humans ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Pharmacology (medical) ,RNA, Messenger ,BNT162 Vaccine ,2019-nCoV Vaccine mRNA-1273 ,Aged - Abstract
International audience; Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and the first epidemiological evidence suggests an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. To 30 June 2021, of 716 928 reports with mRNA COVID-19 vaccines, we found 7728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds ratio 1.9, 95% CI 1.8–2.1). Furthermore, we found a reduced risk of reporting HZ among under 40-year-old persons compared to older persons (reporting odds ratio 0.39, 95% CI 0.36–0.41). Mild and infrequent HZ reactions may occur shortly after mRNA COVID-19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 years old. Further analyses are needed to confirm this risk.
- Published
- 2021
48. PCIP-seq: simultaneous sequencing of integrated viral genomes and their insertion sites with long reads
- Author
-
Elettra Bianchi, Fereshteh Ashrafi, Basiel Cole, Arsène Burny, Michel Georges, Maria Artesi, Olivier Hermine, Natasa Arsic, Keith Durkin, Philip J. Griebel, Vincent Bours, Frank van der Meer, Carole Charlier, Ambroise Marçais, Linos Vandekerckhove, Vincent Hahaut, Laurens Lambrechts, Anne Van den Broeke, Dominique Bron, Philippe Delvenne, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Paris (UP)
- Subjects
Host genome ,HPV ,lcsh:QH426-470 ,Virus Integration ,viruses ,[SDV]Life Sciences [q-bio] ,BLV ,Endogenous retrovirus ,Method ,Computational biology ,Genome, Viral ,Viral genome ,Genome ,Polymerase Chain Reaction ,Polymorphism, Single Nucleotide ,03 medical and health sciences ,0302 clinical medicine ,Retrovirus ,Proviruses ,Infected cell ,Medicine and Health Sciences ,Animals ,Humans ,Clustered Regularly Interspaced Short Palindromic Repeats ,Long-read sequencing ,lcsh:QH301-705.5 ,030304 developmental biology ,Sequence (medicine) ,0303 health sciences ,biology ,Computational Biology ,High-Throughput Nucleotide Sequencing ,HIV ,Genomics ,biology.organism_classification ,Human genetics ,Clonal expansion ,3. Good health ,lcsh:Genetics ,Retroviridae ,Integration site analysis ,lcsh:Biology (General) ,Viral genomes ,HTLV-1 ,NGS ,030217 neurology & neurosurgery ,Hématologie - Abstract
The integration of a viral genome into the host genome has a major impact on the trajectory of the infected cell. Integration location and variation within the associated viral genome can influence both clonal expansion and persistence of infected cells. Methods based on short-read sequencing can identify viral insertion sites, but the sequence of the viral genomes within remains unobserved. We develop PCIP-seq, a method that leverages long reads to identify insertion sites and sequence their associated viral genome. We apply the technique to exogenous retroviruses HTLV-1, BLV, and HIV-1, endogenous retroviruses, and human papillomavirus., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021
49. King Charles VIII of France’s Death: From an Unsubstantiated Traumatic Brain Injury to More Realistic Hypotheses
- Author
-
Fabrice Bartolomei, Johan Pallud, Marc Zanello, Patrice Georges-Zimmermann, Gilles Huberfeld, Romain Carron, Alexandre Roux, Philippe Charlier, Martine Gavaret, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), GHU Paris Psychiatrie et Neurosciences, Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Musée du quai Branly – Jacques Chirac (MQBJC), Institut national de recherches archéologiques préventives (Inrap), Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés (TRACES), École des hautes études en sciences sociales (EHESS)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Ministère de la Culture et de la Communication (MCC)-Centre National de la Recherche Scientifique (CNRS), Stroke Unit, University Hospital Timone, APHM, Marseille, and Centre Hospitalier Saint-Anne (GHU Paris)
- Subjects
Brain hemorrhage ,Medical knowledge ,[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory ,Famous Persons ,Traumatic brain injury ,media_common.quotation_subject ,Ancient history ,Neurosyphilis ,Brain Injuries, Traumatic ,Humans ,Medicine ,Status epilepticus ,History, 15th Century ,media_common ,Cause of death ,business.industry ,Language impairment ,Retrospective diagnosis ,Demise ,medicine.disease ,Medical history ,Surgery ,France ,Neurology (clinical) ,Consciousness ,business - Abstract
International audience; On April 7, 1498, Charles VIII, King of France, attended a game of palm in the ditches of the Château d'Amboise. The 27-year-old King suddenly collapsed and became comatose. He laid down, almost on his own, on a straw mat that was hastily arranged, and he died 9 hours later. His contemporaries perceived his death as a perfect reminder of fatality: a king could die alone in a miserable gallery. All who looked into this curious death had dwelled on the frontal blow to head that the king had sustained right before his demise and had not considered alternative scenarios. The present study, still with limited available evidence, aimed to reexamine the historical account of his death in light of modern medical knowledge. It is virtually impossible that a minor bump with low kinetic energy could kill a 27-year-old man. Many historical accounts of Charles VIII’s life and death, including Italian ambassadors' letters, led us to reconsider the commonly held version and to propose an alternative hypothesis. We have concluded that Charles VIII had experienced an acute consciousness disorder with language impairment that could have been related to an epileptic condition secondary to neurosyphilis. We have discussed whether a more accurate diagnosis for the cause of death could be obtained by a pathological analysis of the King’s remains.
- Published
- 2021
50. Neurological complications of varicella zoster virus reactivation: Prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid
- Author
-
Tiphaine Lenfant, Anne‐Sophie L'Honneur, Brigitte Ranque, Benoit Pilmis, Caroline Charlier, Mathieu Zuber, Jacques Pouchot, Flore Rozenberg, and Adrien Michon
- Subjects
Male ,Behavioral Neuroscience ,Herpesvirus 3, Human ,Humans ,Female ,Meningitis ,Meningitis, Aseptic ,Middle Aged ,Prognosis ,Polymerase Chain Reaction ,Cerebrospinal Fluid ,Encephalitis, Varicella Zoster ,Retrospective Studies - Abstract
VZV infection can involve every level of the neurologic system: from the central nervous system (CNS) to the peripheral nervous system (PNS), including aseptic meningitis. Prognosis seems to differ between these neurological involvements. Prognostic factors remain unknown.This is a retrospective multicenter study including all patients with a positive VZV polymerase chain reaction (PCR) in the cerebrospinal fluid (CSF) from eight centers in Paris (France) between 2011 and 2018. Unfavorable outcome was defined as mortality linked to VZV or incomplete recovery. Modified Rankin Scale (mRS) evaluated disability before and after the infection, with the difference designated as Rankin Delta.Seventy-two patients were included (53% male, median age 51 years, median mRS 0). Immunosuppression was reported in 42%. The clinical spectrum included 26 cases of meningitis, 27 instances of CNS involvement, 16 of PNS involvement, and 3 isolated replications (positive PCR but no criteria for neurological complications from VZV). Antiviral treatment was administered to 69 patients (96%). Sixty-two patients completed follow-up. Death linked to VZV occurred in eight cases. Unfavorable outcome (UO) occurred in 60% and was significantly associated with a higher prior mRS (Odd-ratio (OR) 3.1 [1.4-8.8] p = .012) and the presence of PNS or CNS manifestations (OR 22 [4-181] p = .001, OR 6.2 [1.3-33] p = .03, respectively, compared to meningitis). In the CSF, higher protein level (p .0001) was also significantly associated with a higher Rankin Delta.Neurological complications of VZV with evidence of CSF viral replication are heterogeneous: aseptic meningitis has a good prognosis, whereas presence of CNS and PNS involvement is associated with a higher risk of mortality and of sequelae, respectively.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.